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ABSTRACT 
Breast Cancer (BC) is the most frequently diagnosed cancer; 1:8 women are at risk of 
developing BC in her lifetime. Cancer metastasis causes the majority of deaths in BC patients. 
Moreover, side effects of traditional chemotherapeutic drugs (TCD) impair the quality of life of 
these patients. Discovery and development of safe and effective new therapies is imperative for 
the treatment of BC and targeting metastasis. The goal herein is to further expand the applicability 
of transgenic zebrafish for in vivo xenotransplantation of human BC cells and to screen potential 
chemotherapeutics for toxicity and efficacy. For xenotransplantation, MCF-7, BT-474, and MDA-
MB-231 BC cells were used to canvas the benign and malignant types of BC, respectively. 
Fluorescently-labeled MCF-7, BT-474, and MDA-MB-231 cells and the cytotoxic effect of TCD 
(doxorubicin, 4-hydroxytamoxifen, and paclitaxel) were determined for validation in vitro using 
cell viability assay. Test compounds (extracts of Tinospora crispa and potent microtubule 
inhibitors) were used to determine the cytotoxicity in vitro. Maximally tolerated concentration and 
no observed adverse effect level (NOAEL) of were determined in zebrafish following a waterborne 
exposure to concentrations (1-50 µM) of doxorubicin, 4-hydroxytamoxifen, paclitaxel, and 
curcumin and (10-800 nM) mertansine, ansamitocin P-3, and monomethyl auristatin E (MMAE) 
over 96 hours. NOAELs for paclitaxel, mertansine, ansamitocin P-3, and MMAE were 25, 400, 
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50, and 400 nM, respectively. Zebrafish were xenotransplanted with MCF-7, BT-474, and MDA-
MB-231 cell lines to observe the effects of exposure to microtubule inhibitors on the proliferation 
of cancer cells. After xenotransplanting 50-100 BC cells/larva at 2 days post-fertilization, cell 
growth and migration were imaged at 1 and 5 days post-injection using fluorescent microscopy. 
Paclitaxel (25nM) significantly reduced the proliferation of MCF-7 cell xenografts compared to 
controls, confirming the use of this model for MCF-7 cell xenografts. Mertansine (10 and 200 nM) 
also significantly reduced the proliferation of MCF-7 cells. To our knowledge, this is the first study 
that used paclitaxel in BC xenografts even though it is a widely used chemotherapeutic in the 
treatment of BC. Additionally, NOAEL in vivo and cytotoxic effects of mertansine in zebrafish 
xenografts have not been studied before.  
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CHAPTER I 
INTRODUCTION 
1.1 Breast Cancer 
Breast cancer (BC) is the most frequently diagnosed cancer and represents 25% of all 
cancers detected in women worldwide. According to the American Cancer Society, it is estimated 
that approximately 266,120 women will be diagnosed, and over 41,400 women are estimated to 
succumb to this disease in the United States in 2018. One in eight women is at a risk of developing 
BC in her lifetime (Siegel et al., 2018). BC incidence rose from 1980s and declined in early 2000s. 
The five-year survival rates have increased from 75% to over 90% from 1975 to 2011. 
Considerable progress has been made in the last several decades in the treatment of BC with the 
identification of breast cancer intrinsic subtypes. Leading to a change in classification from ductal, 
inflammatory or invasive to expression of molecular features from a biopsy for estrogen receptor 
(ER), progesterone receptor (PR), and the human epidermal growth receptor 2 (HER2) protein. 
BC is classified on the basis of molecular signatures as ER positive (ER+), PR positive (PR+), or 
HER2 protein positive (HER2+). Approximately 70% of BC is ER/PR+, and 20% of BC is 
HER2+. BC can be positive for two or three receptors at a time or it can be negative for all three. 
This latter scenario is known as triple negative BC (TNBC) (Perou et al. 2000). ER/PR+ BC is 
responsive to treatment with tamoxifen (TAM), HER2 protein positive BC is amenable to 
treatment with Trastuzumab, and therapy options for TNBC are limited to traditional 
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chemotherapy. Doxorubicin (DOX) and paclitaxel (PTX) are also used to treat later stage and more 
aggressive ER+ and HER2+ BC, and thus are applicable to all cases of BC (Ades et al., 2017). The 
poor prognosis of breast cancer is due to the subsequent formation of metastasis in approximately 
30-50% of patients even when they are treated with chemotherapy and endocrine adjuvant 
therapies at early stages of BC (Lin 2013; Roche and Vahdat 2011; Martin et al. 2017). 
 Metastasis 
Metastasis is the spread of breast cancer to other locations in the body and is a highly 
dynamic process (Mansel et al. 2007). Majority of the deaths in breast cancer patients are due to 
the metastasis to different organs, and not the primary tumor itself (Weigelt et al. 2005). Metastatic 
BC is also classified as stage IV breast cancer and patients suffering from stage IV BC have similar 
treatment options available as other stages of BC. Currently, there are no therapeutic agents for 
the prevention of metastasis and BC is considered incurable once it reaches a metastatic stage. The 
approaches for treating metastatic cancer are palliative in nature (Roche and Vahdat 2011).   
The link between motility of the cancer cells and the development of metastasis was first 
suggested by Rudolf Virchow, a German scientist (David 1988). The BC metastasis process, as 
reviewed by Scully et al., involves multiple sequential steps and tumor cells must complete all 
these steps for successful metastasis (Scully et al. 2012). Metastasis initially occurs by invasion 
into surrounding host tissue. The tumor cells disrupt the cell-to-cell adhesions and cell adhesion to 
extracellular matrix (ECM). Cell-to-cell adhesion is largely mediated by the cadherin family and 
in BC metastasis (Li and Feng 2011). Integrins, transmembrane receptors on the components of 
ECM, are responsible for the adherence of tumor cells to ECM (Mego et al., 2010). Transport of 
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tumors from the primary tumor site to distal organs occurs at a single-cell level or collectively in 
a number of cells after intravasation into the blood circulation or lymphatic vessels (McSherry et 
al. 2007). The collective migration occurs in intermediately or highly differentiated lobular 
carcinomas of the breast. However, in poorly differentiated tumors, due to abnormalities in the 
structure and function of the intercellular adhesion proteins, the coordinated cell migration may 
change to single cell migration. The presence of intercellular junctions is vital for the collective 
migration of cancer cells; hence they circulate as emboli in the blood or lymphatic vessels after 
invasion (McSherry et al. 2007). The tumor cells then endure cell cycle arrest and adhere to 
capillary beds in the target organs, occasionally for long periods of time, before tumor cells 
extravasate the parenchyma of the target organ whereby they proliferate and develop angiogenesis 
(Hunter et al., 2008). It is critical that the tumor cells simultaneously evade immunosurveillance 
and apoptosis to survive as tumor cells are undergoing these steps (Fidler, et al., 1978; Hunter et 
al., 2008). Metastasis cannot occur until there is a favorable microenvironment making tumor 
microenvironment a critical factor for this process (Scully et al. 2012).  
Novel anti-cancer drugs are rarely used in metastatic cancer settings, which is a challenge 
in clinical settings as drug candidates are tested in patients with metastatic disease. Neoadjuvant 
therapies in patients with localized cancer are being evaluated to prevent cancer metastasis; to 
determine if the neoadjuvant therapies are helpful in eliminating the disseminated cancer cells 
which lead to formation of metastases. Therefore, for novel anti-cancer drug discovery, it is 
important to simulate conditions which promote the normal proliferation and migration of cancer 
cells for a robust and efficient model. The established in vitro models must have in vivo 
complements in order to gain insights in the molecular mechanisms as well as to elucidate 
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multicellular interactions involved with tumor progression (Vittori et al. 2015). Mouse models are 
traditionally used for screening anti-cancer compounds but have certain disadvantages that limit 
their use to study metastasis. It is difficult to assess early stage metastasis, the metastatic process 
is a long process in mice, and sacrificing the animal is essential to study tumor lesions (Zhao et al. 
2015). Although it is difficult to simulate the metastatic process entirely in zebrafish, certain stages 
of metastasis can be studied. It was observed that tumorigenic human gastrointestinal cells 
metastasize when xenotransplanted in zebrafish and non-tumorigenic tissues do not metastasize 
(Marques et al. 2009). The clinical behavior of tumor cells is also conserved in zebrafish as 
demonstrated by glioblastoma cells injected in the brain and yolk sac which did not metastasize 
beyond the surrounding brain tissue (Lal et al. 2012).  The transgenic zebrafish, being transparent, 
affords us the opportunity to study tumor metastasis in vivo using high resolution microscopy, and 
to observe the in vivo growth patterns of human cancer cell lines in terms of invasiveness and 
response to cytotoxic compounds. Moreover, in zebrafish, the rapid process of metastasis can be 
observed in as soon as two days post injection (Yang et al. 2013). Using targeted disruption of 
proteins and molecules, inhibition of metastasis can be studied in zebrafish. For example, 
inhibition of PDK1/PLCy1 complex using 2-O-Bn-InsP5, a small molecule inhibitor, reduced the 
metastasis of MDA-MB-231 BC cells in 2 dpf zebrafish embryos. The zebrafish embryos were 
injected at different sites including duct of Cuvier and perivitelline cavity, and significantly 
reduced dissemination of tumor cells was observed as compared to controls (Raimondi et al. 2016). 
Similar significant reduction in dissemination of MDA-MB-231 cells was also seen when v-
integrin was knocked down in MDA-MB-231 and by chemically inhibiting v-integrin using 
GLPG0187, suggesting the involvement of v-integrin in metastasis (Y. Li et al. 2015).  
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 Tumor microenvironment 
The presence of a conducive microenvironment for tumor cell proliferation and malignant 
progression is critical for the development of metastases (Psaila et al. 2007). The tumor 
microenvironment consists of fibroblasts, immune cells, mural cells of the blood and lymph 
vessels, along with the ECM and endothelial cells, and the malignant cells interact with these cells 
at the primary as well as the metastatic sites (Folkman and Kalluri 2004; Kalluri and Zeisberg 
2006; Fidler et al. 2007). These multiple types of cells secrete cytokines, growth factors, and 
proteases that may be involved in the invasion and metastasis of BC primary tumors (McSherry et 
al. 2007). The transformation of “in situ” breast cancer to metastatic form is a result of these 
interactions (Coghlin and Murray 2010). The metastatic cascade is complex, and this complexity 
is attributed by the tumor cell biology as well as the entire organism in which the tumor dwells. 
There is limited literature on the microenvironment in zebrafish, however it is possible to study 
the key tumor microenvironment factors in a zebrafish xenograft model. The hematopoietic stem 
cell niche is proposed to be a factor in housing cancer cells to bone marrow. The caudal 
hematopoietic tissue in zebrafish is the area of embryonic hematopoiesis and thought to be 
composed of a bone marrow hematopoietic stem cell niche. Sacco et el injected multiple myeloma 
cells, fluorescently labeled, in the intracardiac region of 2 dpf Casper zebrafish and found tumor 
cells localized in hematopoietic tissue within 30 minutes of injection (Sacco et al. 2016). Another 
group injected multiple tumor cells in the duct of Cuvier found the cancer cells localized in the 
caudal hematopoietic tissue area. They discovered a novel mechanism of formation of the 
metastatic niche and that the site of formation of micrometastasis is determined by the 
physiological migration of neutrophils, and an interplay between VEGF and neutrophils (He et al. 
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2012). These studies point to the relevance of zebrafish in studying the role of hematopoietic niche 
in metastasis.  Zebrafish larvae provide the opportunity to observe the behavior of grafted tumor 
cells by high resolution in vivo imaging techniques and rapid analysis of metastatic behavior of 
human tumor cells (Tobia et al. 2013). Our goal is to employ the transgenic zebrafish 
xenotransplantation model to identify cytotoxic compounds that can be used in the treatment of all 
the BC subtypes. 
 Traditionally used chemotherapeutics 
The available treatment options for BC include a) surgery, b) radiation therapy, c) 
chemotherapy and d) targeted therapy to cell receptors. a) Surgery and b) radiation are invasive 
methods and are more localized, but not feasible for metastasis treatment. The current gold 
standard for treating early stage breast cancer patients is breast-conserving surgery (BCS) with 
adjuvant radiotherapy (Franceschini et al. 2015). c) Chemotherapeutic drugs, on the other hand, 
are potent cytotoxic agents with different mechanisms of action depending on the type of solid 
tumor being treated. Tamoxifen (TAM), DOX, and PTX are the most widely used drugs depending 
on the type of BC. DOX and TAM are the first line treatment for ER/PR+ BC, are associated with 
marked toxicities and long-term adverse events such as lymphedema, neurotoxicity, and 
chemotherapy induced peripheral neuropathy (CIPN) which impair the quality of life of these 
patients (Hershman et al. 2011). For TNBC, there are no specific treatment options available to 
deal with the metastasis, which is the main cause of death in the patients, as the metastasis spreads 
and forms micrometastasis in bones and other organs. However, DOX along with daunorubicin is 
the first line of treatment for patients suffering for this type of BC. As in other types of BC 
subtypes, in TNBC patients as well, there is a development of resistance and they stop responding 
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to the treatment (Ades, Tryfonidis, and Zardavas 2017) pointing to an urgent need for efficient 
therapeutics with minimal side effects.  
Tamoxifen (TAM) is the first line of treatment for ER/PR+ BC, a selective estrogen 
receptor modulator (SERM), which acts as an antagonist for estrogen receptor in breast tissues 
(Rivenbark et al. 2013). Tamoxifen, a nonsteroidal triphenylethylene derivative, is a competitive 
inhibitor of estrogen binding at the ER and blocks estrogen action on the BC cells expressing these 
receptors. Upon binding to the ER, tamoxifen induces the synthesis of cytosine transforming 
growth factor-β (TGF-β) and inhibits the proliferation of these cells by negatively regulating the 
autocrine system (V. C. Jordan 1993; Sawka et al. 1986). Although, with adjuvant therapy, a 35% 
decrease in the BC is seen in patients treated with tamoxifen, patients develop resistance to 
tamoxifen and stop responding to the treatment. Based on the findings of several trials of five years 
of TAM treatment versus no treatment, TAM increased the incidence of endometrial cancer in 
postmenopausal women who had not undergone hysterectomy before trial entry. The overall life-
table calculations for older women suggest in 15 years a 2-3% risk of endometrial cancer if they 
used adjuvant TAM, and if they use TAM for 10 years that would put them at an additional risk 
of 2% in 15 years. However, this risk is lower in premenopausal women (Early Breast Cancer 
Trialists’ Collaborative Group (EBCTCG) et al. 2011; Davies et al. 2013).  
Doxorubicin (DOX) is an anthracycline drug extracted from Streptomyces peuceutius in 
the 1970s and is a routinely used antineoplastic agent in the treatment of various cancers such as 
breast, ovarian, lung, gastric, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma (Thorn et al. 
2011). DOX acts mainly by intercalating the DNA and disrupting the topoisomerase-II-mediated 
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DNA repair leading to DNA damage and cell death. Another proposed mechanism of action of 
DOX is the formation of reactive oxygen species upon oxidation to semiquinone which gets 
converted back to DOX leading to formation of free radicals which damage the DNA, proteins and 
triggers apoptotic cell death pathways in cancer cells (Doroshow 1986; Gewirtz 1999). However, 
the use of doxorubicin is limited by cardiotoxicity and doxorubicin resistance in patients (Thorn 
et al. 2011). In most cancer treatments DOX is rarely administered in isolation but with other 
chemotherapeutic compounds such as taxanes or trastuzumab. Moreover, co-treatment with 
trastuzumab or taxanes also results in cardiotoxicity (Gianni et al., 2007). A combination of 
taxanes and anthracyclines are now widely used as standard first line treatment in advanced stages 
of breast cancer as this combination showed better response rates than standard anthracycline 
based treatment (Ghersi et al. 2005).  
Taxanes (paclitaxel and docetaxel) are widely used to treat breast cancer, especially the 
metastatic anthracycline-resistant breast cancers. Taxanes are associated with adverse side effects 
which include myalgias, peripheral neuropathy, and skin reactions. CIPN, a distal sensory 
neuropathy, is marked by pain, numbness, tingling, and a decrease in the functional capacity in the 
extremities. The other side effects associated with taxanes include ataxia, paresthesia, impairment 
of joint position sense, and a loss in tendon function (Hershman et al. 2011; De Laurentiis et al. 
2008). Randomized trials of taxanes as adjuvant therapy for breast cancer indicated a range of 15-
23% grade 2 and 3 neuropathy based on the NCI (National Cancer Institute) Common 
Terminology Criteria. A grade 2 neuropathy results in mild symptoms affecting functioning 
whereas grade 3 neuropathy greatly affects routine activities. A study conducted to evaluate the 
prevalence and severity of symptoms after adjuvant paclitaxel treatment with median months since 
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last treatment with PTX was 12 months was conducted in 50 women. The study found that 80% 
of the patients who received taxane-based adjuvant chemotherapy for treatment of early stage 
breast cancer experienced neuropathy symptoms up to 2 years after completing the treatment 
(Hershman et al. 2011). 
As patients with TNBC cannot be treated using hormone or targeted therapy, there are 
limited treatment options and chemotherapy is the mainstay. Recent research has identified 
potential new targets for breast cancer drugs. There are five major areas where targeted therapies 
are being extensively studied: a) monoclonal antibodies, b) tyrosine kinase receptor inhibitors, c) 
small molecules targeting molecule-drug conjugates, d) antisense and siRNA approaches, and e) 
antibody drug conjugates (ADCs). These drugs are currently being evaluated in the treatment of 
TNBC as single or combination therapy to discover and develop effective therapies for improving 
the rate of survival, and the quality of life of patients during cancer treatment and post-cancer. 
 Trends in breast cancer drug discovery: 
Targeted therapies aim molecular targets and pathways which are vital for cancer cell 
proliferation. These may be VEGF (vascular endothelial growth factor), tyrosine kinases, 
epidermal growth factor receptor (EGFR), androgen receptor, poly (ADP-ribose) polymerase 
(PARP). By targeting these molecular targets and pathways that the cancer cells depend on to 
proliferate and metastasize, researchers have been able to identify and develop compounds that 
cause selective cytotoxicity in cancer cells with minimized damage to host cells (Nagini 2017). 
The other aspect of targeted therapies is to explore natural products to identify potent anti-cancer 
compounds. However, effectiveness of novel anti-cancer compounds is limited by a lack of 
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selectivity for tumor cells, and potent anti-cancer compounds need to be used close to their 
maximally tolerated dose (MTD) to achieve a therapeutic effect that is clinically effective. In many 
cancer types, a standard modality is to administer a combination of drugs which have different 
mechanisms of action as well as their toxicity profiles do not overlap, thereby improving antitumor 
activity by exhibiting an additive or synergistic anti-cancer effect (Chari et al. 2014). However, 
such regimens render systemic toxicity in the patient and are effective only a small proportion of 
cancers. To overcome the issue of limited clinical efficacy, antibody drug conjugates (ADC’s) 
were developed. ADC’s combine two approaches of targeted therapy- identification of specific 
molecular markers expressed by tumor cells called antigens, using antibodies that target the 
antigens as vehicles for selective drug delivery to the tumor cell, and linking the cytotoxic drug to 
the cytotoxic drug without causing chemotherapeutic damage to non-target tissues (Doronina et 
al. 2003; Chari et al. 2014). 
 Antibody Drug Conjugates (ADC) 
Antibody drug conjugates comprise mainly of three components a) antibody, b) linker, and 
c) cytotoxic drug or payload as shown in Figure 1.   
Antibody- Monoclonal antibodies have been used as targeted therapies in cancer because 
cancer cells express specific molecular markers such as CD33 on malignant blast cells in patients 
suffering from acute myeloid leukemia (Linenberger 2005), CD30 positive Hodgkin/Reed-
Steinberg cells in Hodgkin lymphoma and CD30 positive large anaplastic lymphoid cells in 
systemic anaplastic large cell lymphoma (ALCL) (van de Donk and Dhimolea 2012), and HER2 
positive breast cancer cells (Gutierrez and Schiff 2011) are responsible for the progression and 
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survival of the tumor cells. These tumor-associated antigens should be minimally expressed by 
normal human tissues. The antibody should be well internalized by receptor-mediated endocytosis 
and the target antigen should not be downregulated by the ADC (Perez et al. 2014; Panowski et al. 
2014).  The rate of internalization of the ADC in the cancer cell is a poorly understood process and 
is affected by factors like epitope on the target antigen, high interstitial tumor pressure, 
downregulation of the antigen, and presence of kinetic and physical barriers that diminish the 
cytotoxic payload uptake (Mack et al. 2014; Perez et al. 2014). The antibodies used can be human, 
humanized, and chimeric or mouse. However, the most commonly used antibodies include human 
IGg isotypes. Once part of the ADC, the antibodies can retain their original properties and activate 
immune functions and still act as signal modulators or receptor inhibitors (Xie et al. 2004). 
Currently, there are four approved ADC’s for cancer treatment which are gemtuzumab ozogamicin 
(anti-CD33), brentuximab vedotin (anti-CD30), trastuzumab emtansine (anti-HER2), inotozuman 
ozogamicin (anti-CD22) for acute myelogenous leukemia, anaplastic large cell 
lymphoma/Hodgkin’s lymphoma, HER2+ breast cancer, and acute lymphoblastic leukemia 
respectively (Doronina et al. 2003; Gualberto 2012; Dhillon 2014). 
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Figure 1: Components of an antibody drug conjugate (ADC). 
Linker- The pharmacokinetics, therapeutic index, and efficacy of the ADC is dependent 
on the linkers. Ideally, a linker should be stable and prevent the release of the cytotoxic drug before 
reaching the target, thus preventing off-target toxicity. The linker should be able to release the 
drug once the ADC is internalized. The drug-antibody ratio (DAR) is also critical because 
attaching too few drug molecules may lead to a decrease in the efficacy and attaching too many 
drug molecules may make the ADC unstable. This may lead to altered pharmacokinetics, increased 
plasma clearance, reduced half-life that leads to an increased systemic toxicity (Perez et al., 2014). 
Currently, the licensed ADCs are produced with nonspecific conjugation to lysine residues and 
non-canonical amino acid incorporation or modification of peptide tags (Zhou, 2017). Linkers may 
be cleavable or non-cleavable. Cleavable linkers (acid sensitive, lysosomal protease-sensitive, or 
glutathione-sensitive) increase the possibility of bystander effect (Panowski et al., 2014). For 
screening different antibodies and linkers for the ADC’s, it is important to consider the difference 
in pharmacodynamics and pharmacokinetics when the ADC exposure is waterborne. This also 
applies to solubility of compounds in DMSO or other suitable solvents for waterborne exposures 
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and the concentration of these solvents as hydrophobic compounds or high molecular weight 
compounds cannot be administered in a waterborne exposure. 
Drug or cytotoxic payload: There are two classes of compounds being extensively used 
in the design of payloads, and these compounds and their derivatives are being studied as ADC in 
a number of clinical trials for various solid and liquid tumors. The two classes of compounds are 
microtubule inhibitors and DNA intercalators. The first generation of ADCs used classical 
chemotherapy drugs like doxorubicin and methotrexate and offered the benefit of well-known 
cytotoxic profile. Studies showed that the actual concentration of the cytotoxic payload in the 
tumor cells was minimal with only 1-2% of the administered dose reaching the tumor cells. 
Therefore, the cytotoxic payload used must be highly potent and effective at nanomolar and 
picomolar concentrations (Teicher and Chari, 2011). Since then, extensive research has been 
conducted in the design and selection of payloads, antibodies, and linkers. To optimize the 
therapeutic index of the drug, tumor selectivity is improved to either increase the maximally 
tolerated dose (MTD) or to increase the potency of the cytotoxic drug thereby decreasing the 
minimum effective dose (MED)(Chari et al. 2014).  
 Microtubule inhibitors as payloads: 
Major dynamic structural component of a cell that is vital in the development, reproduction, 
division, and in maintaining the shape of the cell, microtubules are polymers of α and β tubulin 
heterodimers. Microtubules exhibit complex polymerization dynamics which determine and 
regulate their biological functions. The microtubules are polymerized by a mechanism known as 
nucleation-elongation wherein a short microtubule nucleus is formed followed by lengthening of 
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the microtubule at each end with a reversible and noncovalent addition of tubulin dimers (Jordan, 
2002). The complex polymerization dynamics are possible with the binding of tubulin to guanine 
triphosphate (GTP) whereby energy is released by hydrolysis of (GTP) to guanine diphosphate 
(GDP) and Pi at the growing end of microtubules, leaving a microtubule core consisting of tubulin 
with stoichiometrically bound GDP. Until the tubulin subunit dissociates from the microtubule, 
GDP remains non-dissociable and non-exchangeable. There are two dynamic behaviors of 
microtubules, “treadmilling” and “dynamic instability”. In treadmilling, there is a net growth of 
one end of the microtubule and a net shortening of the other end. Dynamic instability involves 
switching of phases between rapid growth and shortening of the microtubule ends, and these 
transitions are regulated by the presence or absence of the region of tubulin-GDP at the 
microtubule end. Growth of a microtubule continues as long as it maintains a stabilizing cap of 
tubulin-GTP or tubulin-GDP-Pi at its end, and the loss of this cap results in depolymerization of 
the microtubule (Jordan et al., 1993; Wilson and Jordan, 1995). Microtubule ends, known as plus 
and minus ends, are not equivalent. The plus end is kinetically more dynamic than the minus end. 
Both ends can elongate or shorten, but changes in length at the plus end are much larger than the 
minus end. Microtubules endure lengthy periods of slow lengthening, short periods of quick 
shortening, and periods of pause. Both treadmilling and dynamic instability occur in living cells 
and are excellently regulated by microtubule associated proteins (MAP) and by drugs (Wilson and 
Jordan, 1995). Microtubules are believed to be a major target for anti-cancer drug discovery 
(Wilson and Jordan, 1995; Jordan et al., 1998; Pasquier and Kavallaris, 2008) and compounds that 
target microtubules, microtubule stabilizers and destabilizers, are widely investigated in anti-
cancer drug discovery (Pasquier and Kavallaris, 2008).  
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 Microtubule inhibitors 
Taxol, a mitotic inhibitor, was isolated from the bark of Taxus brevifolia (northwest Pacific 
Yew Tree) in 1967. It is produced by a fungal endophyte when grown on semisynthetic media, 
first isolated from the phloem tissue of the Pacific Yew Tree (Stierle, Strobel and Stierle, 1993). 
Bristol-Myers Squibb commercially developed this fungal endophyte under the trademark Taxol 
and generic name Paclitaxel (PTX). PTX arrests cells by stabilizing spindle microtubules during 
mitosis (Schiff and Horwitz, 1980; Wilson and Jordan, 1995). PTX has high affinity for 
microtubules, leads to an increase in microtubule polymerization in vitro, boosts both nucleation 
and elongation phases, and it decreases critical tubulin subunit concentration. PTX polymerized 
microtubules are very stable and resist depolymerization by lower temperatures (4 °C) and 
calcium, induces self-assembly of tubulin into microtubules at 0 °C in the absence of GTP, MAP’s, 
and at alkaline pH (Aparajitha and Priyadarshini K, 2012). Although PTX is potent 
chemotherapeutic drug, multidrug resistance developed by tumor cells and restricted drug access 
to the growing tumor cells caused by immune vascularization, tissue hypoxia, reduction in blood 
flow are limitations to tumor responsiveness (Vredenburg et al., 2001). Targeted therapies to 
overcome these limitations are required which can utilize existing potent drugs and their 
derivatives for effective anti-cancer activity.  
Maytansinoids and auristatins are two largest classes of potent microtubule inhibitors 
which are presently utilized as a “payload” of ADC’s in clinical trials (Beck et al., 2017). We 
selected three compounds belonging to the microtubule inhibitor class- maytansinoids and 
auristatins to test their maximally tolerated concentration in vivo, and their effect on BC cell 
proliferation. These compounds are highly potent and reported IC50 values in various solid tumors 
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is in the picomolar and nanomolar ranges. 
 
Figure 2: Chemical structures of monomethyl auristatin e (MMAE), ansamitocin P-3, and 
mertansine. 
Dolastatin 10, a linear peptide, was isolated from Dolabella auricularia, a shell-less marine 
mollusk found in the Indian Ocean. Dolastatin 10 and its derivatives are microtubule inhibitors 
and inhibit the binding of tubulin-GTP, causing a blockage of microtubule dynamics (Pettit et al. 
1998). Auristatins, fully synthetic analogues of dolastatin 10, were identified by SAR studies based 
on dolastatin 10 (Otani et al., 2000). Auristatins block the assembly of tubulin and cause a cell 
Monomethyl auristatin e (MMAE) 
Ansamitocin P-3 Mertansine 
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cycle arrest in the G2/M phase. They are a commonly used cytotoxic payload and comprise of the 
majority of payloads in ADCs being investigated. For our studies, we selected monomethyl 
auristatin e (MMAE), Figure 2, to determine the MTC in larvae over a period of 96 hours. 
Bretuximab vedotin is an approved ADC for the treatment of anaplastic large cell 
lymphoma/Hodgkin’s lymphoma. 
Maytansinoids are another class of potent tubulin inhibitors. They are isolated from the 
Ethiopian shrub Maytenus ovatus by Kupchan et al. in 1972 (Kupchan et al., 1972). Maytansine 
was one of the first compounds found to kill cancer cells with IC50 values in the picomolar range 
and was found to be more cytotoxic than doxorubicin, methotrexate, and 5-fluorouracil. 
Maytansine attaches to tubulin with high affinity for tubulin located at microtubule ends. The 
binding of maytansine to tubulin leads to cytological changes in which chromosomes are scattered 
at random in the arrested cells in metaphase and leads to the formation of multinucleated or large 
cells (Cassady et al., 2004). Maytansine inhibits microtubule assembly by binding to tubulin and 
have KD~ 1µmol/L. Mertansine is a semisynthetic analog of maytansine (Kupchan et al., 1972), 
small molecular weight of 737.5 Da cytotoxic agent (Xie et al., 2004). The intercellular target of 
mertansine is tubulin, and it inhibits the polymerization of tubulin in cancer cells (Xie et al., 2004). 
 Natural products as anti-cancer compounds 
Natural products continue to play a highly significant role in drug discovery and 
development process. Natural compounds have a long and successful history in anticancer drug 
discovery (Newman and Cragg, 2012). Natural products, owing to their chemical diversity and 
biological activities, are attractive candidates for anticancer drug discovery. The National Center 
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for Natural Products Research at The University of Mississippi is one of the largest natural product 
research institutions in the country and has an extensive library of novel compounds isolated from 
plants and other natural sources. Our initial approach was to test novel compounds with unknown 
anti-cancer activity to develop this model as a medium-throughput anti-cancer drug screening tool.  
 Tinospora crispa 
 Tinospora crispa is a herbaceous vine found in Asian and African rainforests and mixed 
deciduous forests (Pathak et al. 1995). Traditionally, this medicinal plant has found use as folk 
prescription in Asian countries like Malaysia, Indonesia, Thailand, and the Philippines for treating 
hypertension, diabetes, urinary disorders, fever, malaria, internal inflammation, rheumatism, 
appetite stimulation, and maintaining good health (Kongsaktrakoon et al.1984) (Rahman et al., 
1999) (Pathak et al. 1995). Phytochemically, T. crispa is composed of diverse secondary 
metabolites. More than 65 compounds have been isolated and identified such as alkaloids, 
flavonoids, and flavone glycosides, lactones, sterols, triterpenes, diterpenes and diterpene 
glycosides, and nucleosides. Clerodane-type furanoditerpenoids are the characteristic compounds 
of T. crispa (Ahmad et al. 2016). Borapetoside A, borapetoside B, borapetol A, borapetol B, 
tinoturbride, tinocrisposide, N-formylanondine, N-formylnornuciferine, N-acetyl nornuciferine 
and picrotein are some of the chemical constituents isolated from T. crispa (Pathak et al. 1995). 
Investigative studies have been performed by different groups of researchers to identify the active 
constituents of T. crispa extracts responsible for diverse activities such as anti-inflammatory, anti- 
diabetic, and anti-cancer activity as described below. 
Abood et. al. evaluated crude ethanol extracts of T. crispa along with its isolated fractions 
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for potential anti-inflammatory activity and observed that the ethanolic extract and its subsequent 
fractions stimulated the murine macrophages from blood (RAW264.7) proliferation in a dose 
dependent manner. The ethanol extract and its fractions increased RAW264.7 at a dose of 25-800 
µg/mL, and improved intracellular expressions of cytokine INF-Υ, IL-6, and IL-8. The ethyl 
acetate fraction was found to be the most active of all the fractions tested, with significant increase 
in intracellular expression of cytokines in RAW264.7 macrophages (Abood, Fahmi and Abdulla, 
2014). Methanolic and aqueous extracts of T. crispa stem reduced the secretion of macrophage 
colony stimulating factor (M-CSF), vascular cell adhesion molecule (VCAM-1), and intracellular 
cell adhesion molecule (ICAM-1) in TNF-α stimulated human umbilical vein endothelial cells 
(HUVECs) (Kamarazaman, Amorn and Ali, 2012). T. crispa aqueous extract in doses of 50, 100, 
and 150 mg/kg significantly inhibited the development of edema in a foot pad thickness 
experiment, exhibiting similar results to ibuprofen (Hipol, Cariaga and Hipol, 2012). 
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Borapetoside C 
 
Borapetoside F (AP-3-29-
3TC) 
 
Borapetoside B (AP-2-60-
2Tc) 
 
Syringin (AP-2-47-5Tc) 
 
Tinosineside A (AP-1-42-4 
Ts) 
 
Tinocordifolioside (AP-1-39-
8 Ts) 
Figure 3: Chemical structures of various constituents of T. crispa tested for cytoxicity in MCF-7 
and MDA-MB-231 BC cells 
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Although numerous compounds have been reported from T.crispa, few have been 
evaluated for cytotoxic activity and the active compounds responsible for cytotoxicity in cancer 
cells still need to be identified. Iqbal et al. reported IC50 > than 10µM for borapetoside A, B, C and 
D in PC-3 cancer cells (human prostate) and normal 3T3 (mouse fibroblast) cell line (Choudhary 
et al., 2010). Mantaj et al. reported selective inhibition of the expression of STAT3 and STAT3 
target genes cyclin D1, fascin and bcl-2 and thus, significant toxicity against STAT3-dependent 
MDA-MB 231 breast cancer cell line by crispene E, a furanoditerpenoid isolated from the hexane 
fraction of T. crispa (Mantaj et al., 2015). The methanolic and other polar fractions of T. crispa 
have been reported to show cytotoxic activity in different cell lines. Froemming observed a dose 
dependent cytotoxic effect in methanolic extract of T.crispa on MDA-MB-231 and MCF-7 cancer 
cell lines with an IC50 value of 44.8 and 33.8 µg/mL (Mantaj et al., 2011). Zulkhairi et. al. studied 
cytotoxic effects of various extracts of T. crispa in different cancer cells such as breast, ovarian, 
and hepatic cancer cells. The aqueous crude extract of T. crispa stem showed IC50 values of 107 
µg/mL in MCF-7 cells, 165 µg/mL in HeLa cells, 100 µg/mL in Caov-3 cells, and 165 µg/mL in 
HepG2 cells. They observed significant cytotoxicity of the crude aqueous extract in comparison 
with cisplatin and tamoxifen, the traditionally used chemotherapeutic drugs. The major 
components with anti-cancer activity still need to be investigated (Zulkhairi et al. 2008). The 
evidence of anti-proliferative activity in cancer cells owing to the active chemical constituents, 
such as diterpenoids and alkaloids, encouraged us to investigate the anti-cancer potential of various 
T. crispa extracts uninvestigated in MCF-7, and MDA-MB-231 breast cancer cell lines. For our 
project, we tested compounds (Figure 3) isolated from T. crispa by Abidah Parveen in the National 
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Center for Natural Product Research. As some of these compounds have not been tested before for 
in vitro cytotoxicity, we tested these compounds using cytotoxicity assays to determine the anti-
cancer activity of various fractions in MCF-7 and MDA-MB-231 BC cell lines. 
 Xenotransplant models: 
Mouse models are traditionally used as “gold standard” for cancer screening (Patel et al. 
2014; Agorku et al. 2016; Tovar et al. 2017; Radiloff et al. 2008; Jung 2014). Advantages of using 
a mouse model for xenograft study include a large number of orthotopic tissues for 
xenotransplantation,  availability of wide range of transgenic mice including humanized, severe 
combined immunodeficient (SCID); and a higher conservation of genes, molecular pathways, and 
organ systems with human beings (Veinotte et al. 2014). However, this model has several 
drawbacks that limit its choice for running rapid anti-cancer drug screening assays. These 
drawbacks include but are not limited to: mice are expensive; the number of pups produced per 
clutch is small, a dedicated facility is required along with personnel which adds up to the costs of 
housing and maintaining these animals. Moreover, tumors take longer (6-8 weeks) to develop in 
mice; it is difficult to monitor tumors grown in non-transparent animals, substantial amounts of 
test compounds are required for administering in mice, and the number of cells required to 
xenotransplant is in the range of ~106/animal. Lastly, the number of animals used per experiment 
is limited to a small number due to these reasons. There is a need to explore other animal models 
to overcome the shortcomings of the mouse model that offer rapid, reproducible, and robust 
outcomes as an alternative xenotransplantation studies.  
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 Transgenic zebrafish as an anti-cancer drug screening model:  
For our project, using transgenic Casper/fli zebrafish as an alternative to the conventional 
mouse model for treating breast cancer, we expect to develop an efficient model to screen the vast 
array of natural compounds available at the University of Mississippi Natural Products Center. 
This screen would enable us to contribute to the discovery of efficacious and safe compounds with 
anti-cancer properties. The ultimate goal of this project is to find and establish the potential of new 
therapeutic compounds for breast cancer that are safe and effective to augment the disease. 
Zebrafish have become an attractive and widely used animal model for various diseases 
including gastrointestinal disorders such as inflammatory bowel disease (Fleming et al. 2010), 
alcoholic liver disease (Lin et al., 2015); brain disorders such as depression (Fonseka et al., 2016), 
and neurodevelopmental disorders such as autism spectrum disorder (Meshalkina et al., 2018); 
muscular dystrophies (Li et al., 2017), cardiomyopathy (Gu et al., 2017), infectious diseases as  
described in a book section by Sullivan et al. (Sullivan et al., 2017); and continues to be explored 
as a model organism in a whole host of other diseases.  
Zebrafish have 70% similarity with human genes that encode proteins, which make 
zebrafish an excellent model to study human diseases related to gene dysfunction (Howe et al., 
2013). This points to high conservation of molecular mechanisms involved in normal and disease 
conditions, and compounds targeting these molecular mechanisms can be closely translated to the 
context of human physio-pathogenesis (Okuda et al., 2016). Comparison of zebrafish and human 
genomes reveal stark conservation in sequence and function of proto-oncogenes, angiogenic 
factors, tumor suppressor, cell cycle, and extracellular matrix proteins (Zon et al., 2013). In 
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addition to the genetic similarities, zebrafish offer practical and logistical advantages as an animal 
model. These include high fecundity, rapid ex-vivo development of the embryos, small size, and 
transparency of the embryo-larval zebrafish. 
Existing zebrafish models have demonstrated human cancer cells, including breast cancer, 
can grow, divide, metastasize, and induce angiogenesis similarly to rodent xenograft models 
(Marques et al., 2009). Moreover, the fish can be easily handled, maintained in small volumes of 
water, transferred into multiwell plates, and pose as a noninvasive cancer model to study the 
exposure-dependent effects on cancer progression using high resolution microscopy (Parng et al., 
2002; Wehmas et al., 2016). Zebrafish embryos lack an active, fully functional adaptive immune 
system until ~28 days which allows implantation of human cells without rejection (Lam et al., 
2004). Easy handling, low costs, and rapidness are unparalleled by other vertebrate organisms and 
make it a promising system in primary tumors (Marques et al., 2009). Cancer cells interact with 
their microenvironment and the whole organism to form cancers. Therefore, the cancer models 
established in vitro must have in vivo complements in order to gain insights in the molecular 
mechanisms as well as elucidating multicellular interactions involved with tumor progression 
(Vittori et al., 2015). Xenografts of various human tumors in zebrafish have been studied over the 
past decade. These xenograft models include tumors of ovaries, lung, breast, prostate, skin, 
leukemia, melanoma. 
For optimal visualization of red fluorescence labeled cancer cells we used a cross between 
Tg(fli1a:EGFP), a transgenic zebrafish line that exhibits a green fluorescent vasculature by 
expressing EGFP under fli1 promoter (Lawson and Weinstein, 2002; Stoletov et al., 2007), and 
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optically transparent Casper zebrafish embryos, developed by White et al. in 2008 (White et al., 
2008a). The crossing procedure is described in the methods section. 
 Patient derived xenografts 
 More recently, zebrafish have been employed to xenograft tumor cells derived from 
patients to test combination therapies against resistant tumor types which are difficult to treat with 
a single conventional therapeutic. Patient derived xenografts (PDX) offer an advantage over 
traditional models of pre-clinical development of oncologic drugs and provide the advantage of 
evaluating the drug sensitivity in patients (Cassidy et al. 2015). Figure 4 is an illustration of the 
processes involved in developing drugs from bench to bedside. PDX in zebrafish have been 
successfully performed by different groups in clinical settings. PDX also offers the opportunity to 
explore molecular events involved in tumor angiogenesis and metastasis, and eventually 
personalized treatment (Gaudenzi et al., 2017). So far, researchers have only been able to establish 
PDX in zebrafish successfully and the dosing is the next step. Neuroendocrine, breast, leukemia 
and other cancers have been successfully xenotransplanted in the zebrafish embryos. These assays 
are fast (3-7 days) and would provide substantial information for a clinician and aid in the 
determination of tailored therapy for the patient (Deveau et al. 2017). Recently, Karkampouna et 
al. xenografted human hepatocellular carcinoma cells (HCC) in zebrafish, mice, and ex vivo to 
determine the expression of CRIPTO, a cell surface protein belonging to TGF-β family that is 
highly expressed in various human cancers, and performed drug response assays in them 
(Karkampouxna et al. 2018). The HepG2 cells expressing CRIPTO were xenografted in zebrafish 
to determine the potential of the cells to migrate and develop tumor foci; combination therapy 
using doxorubicin and sorafenib, standard drugs for HCC treatment, was tested targeting CRIPTO 
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in ex vivo tumor cultures. Similar xenograft experiments using zebrafish are being widely 
performed in clinical settings to determine new molecular targets as well as to determine best 
dosing regimen specifically for the patient. 
 
Figure 4: From bench to bedside, overview of the process of patient derived xenograft drug 
discovery model. 
 Advantages of using zebrafish vs. mouse for xenotransplantation: 
Zebrafish provide an alternative platform for a cancer model that can be traditionally 
accomplished in mouse models (Yen et al., 2014). The comparison between zebrafish and mice as 
xenograft models is summarized in Table 1. Additionally, morpholino injections in zebrafish 
embryos can be utilized to induce a transient block in the translation of gene function and gene 
inactivation, and this technique is fast and easy as compared to generating knock-out mice. Using 
morpholinos, the role of genes involved in angiogenesis can be studied in targeted drug discovery 
of novel therapeutic agents (Tobia et al., 2013). Evaluation of metastasis formation in currently 
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used mouse models take several weeks as compared to zebrafish, where metastasis is observed as 
early as one day post injection (dpi). The zebrafish tumor xenograft model therefore is sensitive 
and allows observation of single cells and their daughter cells in vivo (Marques et al., 2009). 
Moreover, the physiological responses to pharmacologically active compounds in zebrafish 
embryo are comparable to mammalian systems (Zon and Peterson, 2005). Zebrafish embryos 
provide an environment that mimics the human body, including hormones and nutrition. Also, as 
compared to the conventional mouse animal model that requires a dedicated animal facility, 
develops tumor slowly, in our proposed model it is feasible, less tedious and inexpensive to 
xenotransplant 12-30 embryos/treatment group with cancer cells and to study the tumor growth 
and progression in each treatment group. The availability of various tissue-specific fluorescent 
reporter transgenic lines along with transparency of zebrafish has enabled high resolution in vivo 
analysis of tumor cell progression. It also enables us to observe the interactions between host tumor 
microenvironment and the tumor cells (Feitsma and Cuppen, 2008; Binder and Zon, 2013). 
Even with numerous advantages rendering zebrafish as an excellent model for 
xenotransplantation, there are limitations of using this model. For example, the lack of an adaptive 
immune system in zebrafish embryos limits the investigation of the role of the immune system in 
cancer pathogenesis and drug response (Deveau et al. 2017). Zebrafish provide a platform to 
xenograft tumor cells orthotopically, the organs that are not present in fish such as breasts, lungs, 
joints, limbs, and prostate glands. It is also important to note that the drugs that can be tested in 
zebrafish larvae are limited by their characteristics such as molecular weight, solubility, stability 
and bioavailability since the exposures are waterborne (Brown et al., 2017). 
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Table 1: Mice vs. Zebrafish as xenotransplant models. 
 Specific Aims 
The goal of this project was to develop transgenic zebrafish as an in vivo animal model to 
screen anti-cancer compounds for treatment of human breast cancer. The zebrafish larvae 
developed for this study is a fourth-generation cross between Casper and fli strains (CF4), 
possesses a transparent body with fluorescence tagged vasculature. The transparent body allows 
for visualization of BC cells (labeled with red fluorescent dye) which can be traced, and the effects 
of anti-cancer compounds on the tumor cells can also be observed. Our central hypothesis was to 
establish the value of our transgenic Casper/fli zebrafish, using DOX, PTX, 4-hydroxytamoxifen 
(4-OH-TAM), known chemotherapeutic agents used widely as a first line therapy in estrogen-
 
  
Duration of experiment 2-4 months 3-6 days 
Cost $45-60 $1-2 
Maintenance costs $1-3/mouse Cents/tank 
Number of cells required for 
xenografting 
~106/mouse 100-200/larva 
Cancer cell tracking Tumor mass Single cells 
Visualization frequency End point of experiment Everyday 
Histology Individual organs Whole fish 
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dependent/independent breast cancer subtypes. For this, anti-cancer efficacy and potential 
therapeutic index for test compounds in breast cancer cell lines was first established (Aim 1), 
subsequently, we described the maximally tolerated concentration of anti-cancer compounds in 
vivo using zebrafish larvae (Aim 2), and in our final aim 3, we determined the efficacy and 
therapeutic index of the compounds in zebrafish larvae xenografted with human breast cancer cells 
(Aim 3).  
Our experimental approach was accomplished in three aims utilizing in vitro assays and in 
vivo assays. Briefly, three types of BC cells lines were used- Estrogen Receptor positive (ER+, 
MCF-7), human epidermal growth factor 2 protein positive (HER2+, BT-474), and triple negative 
(TNBC, MD-MBA-231) for the evaluation of safety and selectivity of compounds. The in vitro 
assays were followed by in vivo assays to determine the maximally tolerated concentration of the 
extracts and fractions, and the toxic effects, if any, associated with these compounds. The larvae 
were exposed to a range of concentration of different compounds and the maximally tolerated 
concentration was determined over a period of 96 hours. The concentration range determined was 
subsequently administered to xenotransplanted zebrafish larvae to determine the anti-cancer 
potential in an in vivo setting.  
The focus of our work was to establish the transgenic zebrafish as a xenograft model using 
traditionally used chemotherapeutic compounds and then with compounds that have not been tested 
in zebrafish xenografts before. The establishment of this model will offer an opportunity for us to 
screen more novel compounds in zebrafish larvae. We will conduct the following three specific 
aims to establish the transgenic zebrafish xenograft model. 
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 Specific Aim 1- Establish anti-cancer efficacy and potential therapeutic 
index for test compounds in breast cancer cell lines: 
Hypothesis: The effect of the compounds tested (DOX, PTX, Curcumin, T. crispa, and 4-
OH-TAM) on the viability in cell lines (MCF-7, BT-474, and MDA-MB 231 unlabeled and labeled 
with CM-DiI) will be comparable, and the CM-DiI labeled cells do not have sensitivity to the 
compounds related to the dye. 
Approach: Test effect of cytotoxic compounds in MCF-7, BT-474, and MDA-MB 231 cells 
labeled with CM-DiI and evaluate if CM-DiI affects the cellular response to chemotherapeutic 
agents and establish that the agents work as expected. For the latter outcome, 4-OH-TAM should 
demonstrate a measure of inhibited cell growth in ER+ MCF-7 cells and DOX and PTX should 
inhibit the growth of all cell lines. 
 Specific Aim 2- Demonstrate the maximally tolerated concentration 
(MTC) of anti-cancer compounds in vivo using zebrafish: 
Hypothesis: Maximally tolerated concentration (MTC) of chemotherapeutic drugs in the 
zebrafish is comparable to the dose equivalent administered in humans. 
Approach: Expose 3-day post fertilization (3 dpf) larvae to a range of concentrations of 
known cytotoxic and test compounds to determine maximally tolerated concentration (MTC) that 
causes minimal toxicity evaluated as phenotypic developmental defects in the zebrafish. Freshly 
made doses administered every 24 hours and the phenotypic defects observed over a period of 96 
hours. This proposal was approved by IACUC, protocol number- 16-007. 
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 Specific Aim 3: Determine the efficacy and therapeutic index of the 
compounds in zebrafish embryos xenografted with human breast cancer cells.  
Hypothesis: BC tumor burden will be reduced by exposing the zebrafish to the anti-cancer 
compounds DOX, PTX, and 4-OH-TAM and novel test compounds screened in Specific Aim 1.  
Approach: Inject the CM-DiI labeled BC cells in zebrafish embryos and exposed them to 
the safe dose-range of compounds determined in Specific Aim 2 to determine the anti-cancer 
efficacy of each compound by counting and comparing the number of cells in each larva using 
fluorescence microscopy at 1 day post injection and at 5 days post injection. The layout for this 
experiment and the timepoints are illustrated in Figure 5. 
 
Figure 5: Layout of the xenograft experiments. Larvae will be injected with fluorescently 
labeled BC cells at 2 days post fertilization, imaged at 1 day post injection (dpi), and treatment 
will begin at 1 dpi. The treatment continued for 96 hours and on 5 dpi, the larvae were imaged 
again to determine the change in number of cancer cells
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CHAPTER II 
EXPERIMENTAL METHODS 
2.1 Cell Culture 
Cells were cultured and maintained according to the instructions by ATCC (Manassas, 
VA). MCF-7 (ATCC® HTB-22™, provided by Dr. Tracy Brooks), MDA-MB 231 (MDA-MB-
231 (ATCC® HTB-26™, provided by Dr. Shabana Khan), and BT-474 (ATCC® HTB-20™, 
ATCC) cells (Figure 6) were maintained in DMEM media (Life Technologies, CA) supplemented 
with 10% fetal bovine serum (FBS) (Life Technologies, CA) and 1% penicillin/streptomycin 
antibiotics (Sigma-Aldrich, MO) at 37 °C in humid conditions with 5% CO2. Cells were 
maintained in exponential growth phase until needed for experimental procedures.  
 
Figure 6: Breast cancer cell lines used in the in vitro and in vivo experiments. MCF-7 (A), 
MDA-MB-231 (B), and BT-474 (C) were maintained in DMEM media, imaged at 10x 
magnification 
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 Labeling human breast cancer cells with fluorescent dye 
Chloromethyl-benzamidodialkylcarbicyanine dye (CM-DiI) (Thermofisher Scientific, 
CA) is a lipophilic dye that intercalates the plasma membrane of a cell and is reported to be 
expressed by daughter cells for several generations. MCF-7, BT-474, and MDA-MB 231 were 
labeled with CM-DiI according to the manufacturer’s instructions. Briefly, CM-DiI was dissolved 
in DMSO (final concentration: CM-DiI: 4.8 µg/ml, DMSO: 0.4%). Cells were incubated with CM-
DiI cell-labeling solution directly diluted into phosphate-buffered saline (PBS) (2 µL of labeling 
solution per mL of medium) for 4 min at 37 °C, followed by 15 min at 4 °C. The cells were then 
centrifuged at 4000 rpm (2670 x g) for 3 minutes to remove unincorporated dye and rinsed twice 
with PBS. 
 Compounds 
The compounds used were doxorubicin and tamoxifen (provided by Dr. Tracy Brooks), 4-
hydroxytamoxifen (Sigma Aldrich), mertansine (CAS no 139504-50-0, Abovchem), ansamitocin 
P-3 (CAS no. 66547-09-9, Carbosynth), monomethyl auristatin E (CAS no 474645-27-7, 
Advanced ChemBlocks Inc), and curcumin (provided by Dr. Shabana Khan), paclitaxel (Sigma 
Aldrich). Stock solutions of 10 mM were made using DMSO for doxorubicin and curcumin, 
ethanol for 4-hydroxytamoxifen, and tamoxifen, and 1 mM stocks were made for mertansine, 
ansamitocin P-3, MMAE and paclitaxel. The stocks were stored in aliquots at -20 ºC. 
 Cell Viability Assay  
The MTS [(3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium] assay was used to determine the cell viability using colorimetric analysis. The 
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basis of this assay is that tetrazolium is reduced by the NAD(P)H dehydrogenase enzyme in viable 
cells. A colored formazan dye is formed upon reduction which can be detected from its absorbance 
between 490-500 nm (Mosmann, 1983). Breast cancer cells were trypsinized from flasks, 
centrifuged at 4000 rpm (2670 x g) for 5 minutes and resuspended in DMEM. After counting the 
cells, they were diluted with trypan blue in a ratio of 1:10. Trypan blue aids in determining the 
number of dead cells as it is not absorbed by viable cells. The cells were then seeded at a density 
of 5.0 x 103 cells per well in a 96 well plate. 
Cells were allowed to attach overnight, and test compounds were diluted over a 5-6 log 
range from a high dose of 100 µM in case of traditional chemotherapeutic drugs; and 100 nM in 
case of potent microtubule inhibitors, added to the cell plate and allowed to incubate for 24, 72, or 
96 hours.  At the end of the time point, 20 µL of a solution of 2 mg/mL MTS and 5% PMS 
(phenazine methosulfate) (Promega, CA) was added to each well.  The plate was incubated at 37 
°C for 2-4 hours, and absorbance read on a Bio-Tek spectrophotometer (Bio-Tek Instruments, VT) 
at 490 nm. Absorbance was converted into percent cell viability by first subtracting the absorbance 
of the compounds and then normalizing to control cell growth. All experiments had internal 
biological triplicates. GraphPad Prism 5.0 was used to determine the IC50 of each compound by 
non-linear regression with curve fit using dose response-inhibition equation (log[inhibitor] vs. 
response]) with variable slope. For statistical analysis, two-tailed, unpaired t-test with Welch’s 
correction (not assuming equal variances) was used at 95% confidence interval. Anti-cancer 
efficacy was evaluated by the IC50 in unlabeled and CM-DiI labeled MCF-7, BT-474, and MDA-
MB- 231 cells, and for test compounds in the cell lines.  
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2.2 Zebrafish culture  
The transgenic Tg(fli1a:EGFP)y1 zebrafish was generously gifted by Dr. Robert Tanguay 
(Oregon State University) and roya9; mitfaw2 Casper zebrafish was purchased from Zebrafish 
International Resource Center (ZIRC), catalog ID: 1689. Zebrafish were raised according to 
IACUC protocol #14-020 and housed in clean, restricted access facility in Aquatic Habitats Flow-
through System (Aquatic Habitats, Florida). The light cycle for zebrafish was set to 14: 10 hours 
light: dark (dark 22:00 -08:00) to simulate natural breeding conditions. 
The parameters for zebrafish water were set between a range of 26-30°C for temperature; 
pH 7.4-8; conductivity was adjusted using Instant Ocean salt at 60 ppm. The adult zebrafish were 
fed twice daily with Gemma 300 micro food. Larvae at age 5 dpf were fed Gemma 75 micro twice 
daily, and larvae at 30 dpf were fed Gemma 175 micro twice daily. For collecting eggs, mature 
zebrafish were spawned once a week in a spawning trap tank in the ratio of 1:1 male to female. 
Approximately two hours after the onset of the light cycle, the eggs were collected from the 
spawning tank. The eggs were washed, dead and unfertilized eggs removed, and added into a 
petridish containing zebrafish embryo water (sterilized deionized water, pH 7.4-7.7, 60 ppm 
Instant Ocean). The eggs were incubated at a temperature of 28°C and the light cycle was set to 
14:10. Subsequently, the dead embryos were removed, and embryo water was replaced as required 
until the larvae were 5 dpf, at which point they were transferred in a regular tank in the zebrafish 
system. For xenotransplant experiments, the eggs collected from F3 crosses were incubated at 
34°C. 
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 Crossbreeding zebrafish  
The Tg(fli1a:EGFP) transgenic zebrafish expresses the enhanced green fluorescent protein 
throughout their life owing to the fli1a promoter in their endothelial cells. Casper transgenic 
zebrafish, on the other hand, possess roya9; mitfaw2 genes in their homozygous recessive allelic 
form. The roya9 gene imparts transparency while the mitfaw2 gene makes them devoid of pigment 
(White et al., 2008b). For optimal imaging of the fluorescently labeled cancer cells in the fish, it 
was imperative that the fish were transparent, lacked pigment, and had the EGFP labeled 
vasculature. This ensured no interference of the inherent pigment of the zebrafish larvae in 
capturing images of the CM-DiI labeled BC cells in the xenografted fish. The Tg(fli1a:EGFP) and 
Casper transgenic lines were maintained and bred independently, and subsequently spawned 
together to obtain the hybrid transgenic embryos. The hybrid lines were maintained and bred to 
stock for experiments. The crossing technique was optimized by Dr. Faisal Albaqami. We repeated 
his methods and obtained Casper X Tg(fli1a:EGFP)  crosses. Briefly, adult Tg(fli1a:EGFP) males 
and Casper females were spawned in a ratio of 1:1 in the breeding tanks. The eggs were collected, 
washed, and dead ones were removed. Eggs were maintained in a petridish containing zebrafish 
embryo water. These embryos were representative of the first generation (F1) crosses. The F1 
crosses possessed heterozygous dominant wildtype and recessive mutated forms of roya9; mitfaw2 
genes as a result of equal distribution of parent alleles. As a result, the F1 zebrafish expressed the 
EGFP under the fli1a promoter and appeared similar to Tg(fli1a:EGFP) and all embryos express 
green fluorescence in their vasculature. All the embryos were screened at 1 dpf for fluorescence 
and the strong EGFP expressing embryos were selected to be raised. These embryos, upon 
maturation, were spawned among themselves similarly, in the ratio of 1 male to 1 female and the 
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eggs were collected. The eggs collected from the F1 spawning were the F2 generation. F2 crosses 
expressing the EGFP were selected at 2 dpf and raised. The F2 crosses possessed EGFP, but there 
were different phenotypes owing to inheritance patterns as shown in Figure 7. The F2 transgenic 
embryos were raised, and upon reaching adulthood, bred to obtain the third generation (F3), and 
the procedure was repeated to obtain F4 offspring. All zebrafish experiments for this research were 
done using F4 offspring that possessed recessive mutated forms of roya9; mitfaw2 genes and 
expressed EGFP under flia promoter. 
 
Figure 7: Schematic representation of Casper and Tg(fli1a: EGFP) crosses as described in Dr. 
Faisal Albaqami’s dissertation (2016). 
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2.3 Maximally tolerated concentration (MTC) and no observed adverse effect 
level (NOAEL) in zebrafish larvae 
Maximally tolerated concentration (MTC) is the highest concentration at which the 
survival of the zebrafish larvae at the end of a 96-hour exposure was more than 80%, and no 
observed adverse effect level (NOAEL) is the concentration of compound at which deformities 
(curved body axis, yolk sac, and pericardial edema) were not observed in larvae exposed for a 
period of 96 hours. Zebrafish larvae aged 3 days post fertilization (dpf) were exposed to different 
concentrations of the test compounds for 96 hours to determine MTC in the exposed larvae. Each 
treatment group comprised of 12 larvae and corresponding controls treated with embryo water. 
Every 24 hours, the larvae were observed under a microscope to determine survival and for any 
visible phenotypic defects. Ultimately based on MTC and NOAEL, an optimal concentration of 
each compound that did not cause any overt developmental defects or toxicity in the fish was 
determined. 
2.4 Xenotransplantation  
 Preparing cells for transplantation 
Cells (MCF-7, BT-474, and MDA-MB-231) were prepared for transplantation using 
labeling procedure as described in 2.1. The pellet was resuspended in 300 µL serum free DMEM. 
The labeled cells (100-200) were injected in zebrafish embryos within 2 hours to avoid clumping 
of cells. 
39 
 Preparation of zebrafish for microinjection 
The F3 adult zebrafish were spawned two days before the microinjection. Eggs were 
collected the next morning, dead ones removed, and incubated at 34ºC. At 1 dpf, the eggs were 
examined for fluorescence and the embryos expressing EGFP were selected. At 2 dpf, the embryos 
were anaesthetized using 0.02% tricaine methanesulfonate and oriented them in the dorsal position 
in a petridish coated with agarose gel. The borosilicate capillaries were pulled using Sutter 
Instrument P-20 ( pull = 20, velocity = 50, time = 200, pressure =200, and heat = ramp +21°C) as 
suggested by Wehmas et al (Wehmas et al., 2016). 
 Xenotransplant of CM-DiI labeled MCF-7, BT-474, and MDA-MB-231 
cells in zebrafish larvae/embryos 
Xenotransplantation of the breast cancer cells in 2 dpf zebrafish embryos using a protocol 
similar to the procedure described previously (Haldi et al., 2006). The number of labeled cancer 
cells/mL were approximately 1x106. This pellet was resuspended in 300 µl of serum-free DMEM 
and 4-5 µl of this suspension was added to a pulled needle using Eppendorf capillary tips. Five µl 
of the labeled cell suspension was added to each needle. The needle was then inserted in the orifice 
of the micromanipulator and trimmed using forceps. The tip of the pulled needle was then trimmed 
using forceps to allow a droplet of approximately 5 nL to be injected into each fish. The number 
of cells in each droplet was counted and the diameter of the droplet measured to determine the 
number of cells/injection. The optimization procedure is described in Appendix I. The total number 
of cells/injection were calculated to be about 100-200 in a droplet with a radius of 160 µm. 
Borosilicate needles were used to microinject CM-DiI labeled MCF-7, BT-474, and MDA-MB-
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231 cells in the yolk sac of 2 dpf zebrafish embryos. The microneedle was positioned at a 45-
degree angle to inject approximately 50 nL of the cell suspension into the yolk-sac of the larvae; 
100-200 cells per larva were injected, approximately n = 60 larvae were injected for each 
experiment. 
2.5 Quantification of breast cancer cell proliferation  
 Preparation and mounting of xenotransplanted zebrafish for 
fluorescence microscopy 
At 1 dpi, the xenotransplanted zebrafish larvae were anaesthetized in a 0.02% tricaine 
solution and then mounted in 110 µL of 0.8% low melt agarose in tricaine in 48 well plates. The 
agarose gel was allowed to cool down before adding anaesthetized larvae in each well. The larvae 
were positioned using a pipette tip in a lateral position to image the yolk sac. The imaging was 
done at 1 dpi to identify the fish with cancer cells and remove the ones that did not have cancer 
cells or were deformed. After imaging the larvae and selecting the ones with the tumor cells at 1 
dpi, the larvae were exposed to different concentrations of each compound with 20-30 
larvae/treatment (approximately 30 larvae were injected for each treatment group, but at 1 dpi 
some of them died, had edemas, or did not have cancer cells and were eliminated from further 
evaluation) in 48 well plates. The larvae were exposed to the compounds at concentrations 
determined from the in vitro IC50 values and the in vivo MTC and NOAEL assays in water for 96 
hours in 48 well plates. The effect of these compounds on the malignant cells was then observed 
as the distance traveled by the cancer cells from the site of injection after treatment with the 
compounds. In Trial 1, MCF-7, BT-474, and MDA-MB-231 xenografted larvae were treated with 
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10 nM mertansine (n = 12) for comparison of metastatic behavior in three cell lines. Subsequently, 
in Trial 2, MCF-7 xenografts were treated with 10 nM mertansine and 25 nM PTX in three 
independent experiments (n = 6-19). In Trial 3, MCF-7 xenografts were then treated with 200 nM 
mertansine in three independent experiments, and MDA-MB-231 xenografts were treated with 200 
nM mertansine and 25 nM PXT in two independent experiments. The xenografted fish were 
exposed to the selected concentration of compounds for 96 hours starting at 1 dpi, observed every 
24 hours for morphological changes and mortality, and the dose refreshed. After the 96-hour 
dosing period, living larvae were imaged similarly at 5 dpi to determine the proliferation and 
metastasis of cancer cells and the effect of treatment on the number of cancer cells.  
 Imaging the xenotransplanted zebrafish larvae 
The xenotransplanted larvae were imaged using Nikon Eclipse Ti2 microscope using 
triggered tetramethylrhodamine isothiocyanate (TRITC) (excitation wavelength 550 nm and 
emission wavelength 580 nm) and fluorescein isothiocyanate (FITC) (excitation wavelength 494 
nm and emission wavelength 518 nm) acquisition, where both TRITC and FITC wavelengths were 
emitted simultaneously. The exposure times used for TRITC and FITC filters were 200 
miliseconds with 100% and 50%, intensities respectively. We obtained z-stacks of the fish using 
triggered FITC and TRITC settings and 10x + 1.5x objective was used. Each z-stack was 15 µm 
thick. The images were acquired using NIS Elements software (Nikon).  
 Analysis of images obtained 
The fluorescent images were analyzed by selection of every second z-stack slice. The 
TRITC look up table (LUT) was adjusted to eliminate background and autofluorescence, and was 
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kept at the same LUTs for the entire fish. The site of injection was determined, and graticules 
(concentric circles starting at the site of injection then moving out, 100 microns apart) were 
centered on the site of injection. Each circle moving out from the site of injection was 100 µm 
away along the entire length of the fish as shown in Figure 8. Next, cells were manually counted 
using only the TRITC filter image. The number of cells were counted from each selected z-frame 
and in every 100 µm ring. The percent incidence of the number of cells that traveled beyond 
distances of 500, 1000, 1500, 2000, and 2500 nm from the site of injection were calculated. Data 
was analyzed using GraphPad Prism 5.0 and Two-way ANOVA was performed to determine 
statistical significance using Sidak’s multiple comparisons.  
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Figure 8 Pictomicrograph showing xenografted larva at 5 dpi (A) and in (B) the cell counting 
procedure using graticules in blue, each at a distance of 100 microns away from the site the 
injection. The green plus sign indicates each individual breast cancer cell. Number of cells in 
each graticule were manually counted. 
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CHAPTER III 
ZEBRAFISH AS AN IN VIVO SCREEN FOR COMPOUNDS WITH ANTI-
CANCER ACTIVITY IN HUMAN BREAST CANCER  
3.1 Results 
 Determination of in vitro cytotoxicity in labeled vs unlabeled breast 
cancer cell lines  
To determine if the breast cancer cell lines that were labeled with CM-DiI possessed 
different sensitivity to standard chemotherapeutic compounds as compared to the unlabeled cells, 
MCF-7 and MB-231 cells were plated and treated with a log dose range for 72 hours. Figure 9 
shows the treatment of MCF-7 cells with DOX and 4-OH-TAM. The IC50s of doxorubicin and 4-
OH-TAM in labeled and unlabeled cells were 0.33 ± 0.41 µM and 0.47 ± 0.038 µM, and 27.48 ± 
0.52 µM and 28.80 ± 0.71 µM, respectively. A significant difference in the IC50s of labeled vs 
parental cell lines was neither observed, for 4-OH-TAM (n = 3, p = 0.0578, two-tailed unpaired t-
test) nor for DOX (n = 3, p = 0.2288, two-tailed unpaired t-test) 
Tinospora crispa extracts (Table 3) were tested in both labeled and unlabeled MCF-7 and 
MDA-MB-231 cells at concentrations ranging up to 100 mg/mL (Figure 10). Only data from the 
unlabeled experiments is shown. No cytotoxic effects were observed at any concentration of the 
ten extracts. 
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Next, the potent microtubule inhibitors, mertansine, ansamitocin P-3, and MMAE were 
tested in vitro in MCF-7, BT-474, and MDA-MB-231 labeled and unlabeled cells (results shown 
in Appendix I) in multiple batches and repetitions to encompass a wide range of concentrations. 
Initially, it was challenging to get a stable solution of PTX, and it required multiple attempts and 
repetitions to achieve a stable solution where PTX did not precipitate out of solution. The ultimate 
concentration of PTX that was stable in DMSO was 1 mM and the freshly prepared stock was 
stored at -20°C in aliquots. Mertansine and PTX IC50 values in MCF-7 cells were 0.120 ± 0.02 µM 
and 0.39 ± 0.06 µM, respectively. For MDA-MB-231 cells, the IC50 values for mertansine and 
PTX were 0.09 ± 0.02 µM and 0.26 ± 0.04 µM, respectively. In BT-474, the IC50s were 0.11 ± 0.03 
µM and 0.57 ± 0.1 µM, respectively (Figure 11). Mertansine was most cytotoxic in MDA-MB-
231 cells with an IC50 value of 0.09 µM whereas PTX was most toxic in MCF-7 cells. 
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Figure 9: Determination of potential sensitivity to CM-DiI in MCF-7 labeled and unlabeled cells 
after treatment with 4-OH-TAM and doxorubicin. The cells, in triplicate wells, were exposed to 
drugs for a period of 72 hours. No statistically significant difference was found in the IC50’s of 
labeled vs unlabeled cells in response to the treatment tested using a two-tailed unpaired t-test with 
Welch’s correction without assuming equal variance at 95% confidence 
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Table 2: Tinospora crispa fractions tested in MCF-7 and MDA-MB-231 cells for cytotoxicity 
  Compound 1 AP-3-39-3TC 
Compound 2 T. Crispa methanolic extract 
Compound 3 Tinosineside A (AP-1-42-4 Ts) 
Compound 4 AP-TC-But 
Compound 5 T. Crispa ethyl acetate fraction 
Compound 6 T. Crispa chloroform fraction 
Compound 7 Borapetoside E (AP-3-29-3Tc) 
Compound 8 Borapetoside B (AP-2-60-2Tc) 
Compound 9 Borapetoside F 
Compound 12 Syringin (AP-2-47-5Tc) 
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Figure 10: Determination of cytotoxicity of Tinospora crispa fractions in MDA-MB-231 and 
MCF-7 cells. The cells, in triplicate wells, were exposed to Tinospora crispa fractions (see Table 
3 for fractions corresponding to legend numbers) for a period of 72 hours. No toxicity was 
observed in either cell line upon treatment with these compounds for a period of 72 hours. 
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Figure 11: Determination of cytotoxicity of mertansine and paclitaxel in A) MCF-7, B) BT-474, 
and C) MDA-MB-231 cells. The cells, in triplicate wells, were exposed to different concentrations 
of mertansine and paclitaxel for a period of 24 hours 
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.  
 Determination of NOAEL and MTC of test compounds in zebrafish: 
 
Figure 12: Survival of zebrafish larvae after an exposure to different concentrations of 
doxorubicin, pravastatin, curcumin, and 4-OH-TAM (n=12) to determine the maximally tolerated 
concentration in the larvae. The exposure started at 3 days post fertilization (dpf), doses were 
renewed every 24 hours up to 96 hours and the deformities were also noted. 
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Three-day old zebrafish larvae were plated in 48 well plates, one fish per well, and were 
dosed with varying concentrations of compounds for a period of 96 hours. The test chemical was 
re-administered every 24 hours and the larvae were observed for any deformities. The percent 
incidence of deformities observed at MTC in mertansine, ansamitocin P-3, MMAE and PTX are 
listed in Table 4. The MTC and the NOAEL were determined after the end of the exposure and a 
concentration lower than MTC was used as treatment for the xenotransplanted larvae. Observed 
MTCs for doxorubicin, 4-OH-TAM, PTX, curcumin, pravastatin, mertansine, ansamitocin P-3, 
and MMAE are listed in Table 3 below. For MMAE, 83% and 91% of the larvae survived at 
concentrations of 700 and 800 nM, but higher incidences of deformities were noted at these 
concentrations. For mertansine and PTX, the MTC was determined from three independent 
experiments (Figure 14), and we selected 25 nM for PTX, and 10 and 200 nM mertansine as the 
therapeutic concentration in our xenograft experiments. 
  
52 
 
 
Figure 13: Survival of zebrafish larvae after an exposure to different concentrations of potent 
microtubule inhibitors to determine the maximally tolerated concentration in the larvae (n = 12). 
The exposure started at 3 days post fertilization (dpf), doses were renewed every 24 hours up to 
96 hours and the deformities were also noted. 
  
53 
 
 
Figure 14: Survival of zebrafish larvae after an exposure of 10-100 nM of PTX and mertansine 
(n = 12). 
Table 3:.MTC and NOAEL determined for various anti-cancer compounds 
Compound MTC NOAEL 
Doxorubicin 6.5 µM NM 
Curcumin 0.5 µM NM 
Pravastatin 40 µM NM 
Paclitaxel 100 nM 25 nM 
Mertansine 800 nM 400 nM 
Monomethyl auristatin E 800 nM 400 nM 
Ansamitocin P-3 100 nM 50 nM 
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Table 4: Percent incidence of deformities observed in larvae at MTC 
 
 Validation of transgenic zebrafish as a xenotransplant model for human 
breast cancer: 
Three sets of trials (Table 6) aimed at answering questions about the validation of zebrafish 
as a xenotransplant model were performed. In the first experimental group, Trial 1, the metastatic 
behavior of MCF-7, BT-474, and MDA-MB-231 cells in vivo was observed at 1 and 5 dpi (Figure 
15 and 16, respectively). Counting and analysis of cancer cells in the xenografts at 1 dpi showed 
in only a few zebrafish larva the cancer cells traveled beyond 600 micrometers from the site of 
injection (Figure 15). The larvae were then randomly distributed into control and treatment groups 
(n = 12), and treated with 10 nM mertansine. As it was observed that not many cells in either of 
the three experimental groups traveled beyond a distance of 500-600 micrometers from the site of 
injection at 1 dpi, it would be worthwhile to assess the total number of cells in each xenograft at 5 
dpi, as well as to determine the number of cells that traveled beyond the 500 µm distance mark as 
this was the farthest distance traveled by the cells in any of the three xenograft experimental 
groups. At 5 dpi, the total number of cells in the larvae as well as the percent incidence of cancer 
cells that traveled a beyond 500 micrometers from the site of injection in each larva at 5 dpi was 
determined in control and treatment groups. The effect of treatment on distance travelled by the 
Compound 
Percent incidence of deformity observed at MTC 
Yolk sac/Pericardial 
edema 
Curved body axis 
Mertansine 30 60 
MMAE 50 90 
Ansamitocin P-3 45 65 
Paclitaxel 40 50 
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cancer cells from the site of injection in larvae xenografted with the three different cell types 
xenotransplanted was evaluated. Comparison of the total number of cells between the three BC 
xenograft experimental groups suggests that there was no significant difference in the metastatic 
potential of MCF-7, BT-474, or MDA-MB-231 cells or in the percent incidence of cells that 
traveled beyond 500 µm in the three cell lines in Experiment 1(n = 12, One-way ANOVA) (Figure 
17).  
For MCF-7 xenografts, in 25 nM PTX treated larvae in two of three experiments in Trial 
2, a 50-60% decrease (Figure 18) in the fold change of percentage of cells beyond 500 µm from 
the site of injection and in fold change in total number of cells as compared with controls was 
observed. This decrease was consistent with the overall significant reduction of percentage of cell 
that traveled beyond 1000 µm in PTX treated group (Figure 19 (B)) (n = 6-10, One-way ANOVA, 
p <0.05). For MDA-MB-231 xenografts, in 25 nM PTX treatment groups, there was a 10-20% 
decrease in the fold change in percentage of cells beyond 500 µm and fold change in total number 
of cells as compared to controls. A 55% decrease in the total number of cells was also observed in 
the 25 nM PTX group as compared to controls. However, a significant reduction of the percent 
incidence of cells beyond 500 and 1000 µm in PTX treated larvae was not observed. These data 
point to effectiveness of 25 nM PTX in MCF-7 and MDA-MB-231 xenografts. 
For MCF-7 xenografts treated with 10 nM mertansine, a 50-60% reduction in fold change 
in percentage of cells beyond 500 µm and 20-30% decrease in fold change in total number of cells 
as compared to controls was observed in three out of four experiments. Also, a significant 
reduction in tumor burden beyond 500 and 1000 µm from the site of injection was observed in the 
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10 nM mertansine treatment groups (Figure 19) (n= 6-13, One-way ANOVA, p<0.05. In MDA-
MB-231 xenografts in the 10 nM mertansine treatment group, approximately 10% reduction was 
observed in the fold change in percentage of cells beyond 500 µm and fold change in total number 
of cells as compared to controls. However, 10 nM mertansine was not effective in reducing tumor 
burden in MDA-MB-231 xenografts as compared to controls.  
For MCF-7 xenografts treated with a higher concentration of mertansine, 200 nM, it was 
observed that a 20-60% decrease in the fold change in percentage of cells beyond 500 µm and 40-
50% decrease in fold change in total number of cells as compared to controls was observed in four 
experiments. Overall, a 75% reduction in the fold change in percentage of cells beyond 500 µm 
was observed in 200 nM mertansine groups. Interestingly, a significant reduction in the total 
number of cells, percent incidence of cells beyond 500 µm, and 1000 µm was observed in the three 
experiments with 200 nM mertansine treatments (Figure 19) (n= 4-15, One-way ANOVA, 
p<0.05). In MDA-MB-231 xenografted larvae treated with 200 nM mertansine, there was a 10% 
reduction in tumor burden beyond 1000 µm as compared to controls but it was not significant (n 
= 22, One-way ANOVA). 
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 Table 5 Trial 1-Determination of metastatic behavior of MCF-7, BT-474, and MDA-MB-231 
cells in zebrafish xenografts 
 
 
  
 Exp 1 (MCF-7) Exp 2 (MDA-MB-231) Exp 3 (BT-474) 
 Ctrl 
Mert 
(10 nM) 
Ctrl 
Mert 
(10 nM) 
Ctrl 
Mert 
(10 nM) 
Average total 
number of cells 
290±80 208±60 288±67 209±75 202±70 147±80 
Total number of 
fish at 5 DPI/ 
Total number at 1 
DPI 
12/20 12/20 12/20 12/19 12/22 12/21 
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Figure 15: Zebrafish larvae xenografted with the three BC cell lines were imaged for detection of 
cancer cells at 1 dpi and randomly sorted into control and treatment groups. The images for larvae 
that survived until 5 dpi in both control and treatment groups were then analyzed for the distance 
traveled by cancer cells from the site of injection in each larva at 1 and 5 dpi. Distance traveled by 
MCF-7 cells in A) control group and D) treatment group, BT-474 cells in B) control group and E) 
treatment group, and MDA-MB-231 cells in C) control group and F) treatment group.  
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Figure 16:Zebrafish larvae xenografted with the three BC cell lines were imaged at 5 dpi. 
Distance traveled by MCF-7 cells in A) control group and D) treatment group, BT-474 cells in 
B) control group and E) treatment group, and MDA-MB-231 cells in C) control group and E) 
treatment group. 
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Figure 17: Trial 1 with MCF-7, BT-474, and MDA-MB-231 cells xenografted in zebrafish larvae. 
A) Total number of cells in MCF-7, BT-474, and MDA-MB-231 xenografts in the control group 
at 5 dpi  (n = 12). B) Percent incidence of cells beyond 500 µm from the site of injection in MCF-
7, BT-474, and MDA-MB-231 xenografts in the control group at 5 dpi  (n = 12). 
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Figure 18: Fold change in A) percentage of cells beyond 500 µm, and B) in total number of cells 
in MCF-7 xenografted larvae treated with 25 nM Paclitaxel as compared with controls in each of 
three experiments. N = 9-15 
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Figure 19:Percent incidence of cells that traveled beyond A) 500 µm and B) 1000 µm in Trials 
1, 2, and 3 in zebrafish larvae xenografted with MCF-7 cells at in Trials 1, 2, and 3 at 5 dpi. Data 
analyzed using one-way ANOVA, *(p<0.05) and ***(p<0.0001) (n = 4-13). 
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3.2 Discussion 
We hypothesized that zebrafish larvae xenografted with human breast cancer cells and 
treated with traditionally used chemotherapeutics would exhibit a decrease in the number of cancer 
cells throughout the body of the zebrafish larvae as compared to the untreated controls. Three 
different breast cancer cell lines which encompass the three subtypes of breast cancer- ER/PR+ 
(MCF-7), HER2+ (BT-474), and TNBC (MDA-MB-231) were used. The characteristics that 
define these subtypes include, but are not limited to, their metastatic potential which attributes 
aggressiveness to the breast cancer cells. Zebrafish xenografts of human breast cancer represent 
an interplay between tumor and host cells, and the subsequent upregulation or downregulation of 
molecular signals facilitate migration of the tumor cells to different organs in the host. Our model 
offers the opportunity to study molecular mechanisms that are involved in the metastatic processes 
and to understand the role of key players.  
The fluorescence of cancer cells is vital in the screening studies as it makes visualization 
and tracking of cancer cells in vivo feasible using live animals under a fluorescence microscope. 
Determining if the CM-DiI dye labelling makes the cells differentially sensitive to test compounds 
was important as it could affect the interpretation of the results. We did not find any significant 
difference in the IC50 values when labeled and unlabeled breast cancer cells were treated with the 
test compounds (Figure 9). Similarly, in order to determine if the labeled cells behaved differently 
or if there were artifacts produced by the dye, Ghotra et al. (2012) transfected PC3 prostate cancer 
cells with mCherry, and injected zebrafish larvae with labeled CM-DiI as well as mCherry labeled 
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PC3 cells. They did not find any significant changes in the migration pattern of the tumor cells in 
the two groups (Ghotra et al., 2012). Our results from the in vitro cytotoxicity studies also indicate 
that CM-DiI is a reliable tool to label and observe the metastatic patterns and in determining anti-
cancer potential of established and test compounds in vitro, and literature supports its use in vivo. 
Potent microtubule inhibitors used in this study-mertansine, ansamitocin P-3, and MMAE were 
tested in all three BC cell lines to determine their cytotoxicity. IC50 values for mertansine and 
MMAE are not available for MCF-7, BT-474, and MDA-MB-231 cell lines in the literature. The 
IC50 values for these compounds are listed in Table 7.  
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Table 6 IC50 values of microtubule inhibitors in literature 
The NOAEL of different compounds, standard chemotherapeutics used in BC treatment, 
and test compounds with potential anti-cancer activity, was determined in zebrafish larvae for a 
period of 96 hours starting at 3 dpf (Table 4). The NOAEL and MTC provide a range of safe dosing 
concentrations that can be used in the xenograft assays. In most published xenograft studies using 
zebrafish, the xenografted larvae are dosed with a range of concentrations of known or test 
compounds to determine the cytotoxic effect on the tumor cells. In our study, we first determined 
the safe dosing range in un-injected larvae before treating the xenografts. This, in addition to the 
in vitro IC50 values, provides us with a wide range of concentrations for exposure in the xenografts. 
We used 25 nM for PTX, and 10, and 200 nM for mertansine in the xenografts as concentrations 
observed as NOAEL. In mice, PTX is administered i.v./i.p. or in the tail at a concentration of 10 
mg/ml in a solution of cremophor (Ma et al., 2015) whereas in humans, for treatment of metastatic 
breast cancer, concentration up to 175 mg/m2 is administered over three hours every three weeks. 
 
Mertansine MMAE Ansamitocin P-3 
IC50 in vitro 
(literature) 
1.10 nM SK-Br-3 and 
KB (Wayne C. 
Widdison et al., 2006) 
0.1 nM H3396 breast 
carcinoma (Doronina 
et al., 2006) 
• 0.02 nM MCF-7 
• 0.150 nM MDA-
MB-231  (Venghateri 
et al., 2013) 
IC50 values 
(our results) 
• 0.120 ± 0.02 µM 
MCF-7 
• 0.09 ± 0.02 µM 
MDA-MB-231 
• 6.7 ± 2.6 µM 
BT-474 
• 0.150 ±0.02 µM 
MCF-7 
• 0.050 µM MDA-
MB-231 
• 0.04 ± 0.01 µM 
BT-474 
• 0.095 ± 0.03 µM 
MCF-7 
• 0.07 µM MDA-
MB-231 
• 0.049 ±0.01 µM 
BT-474 
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In patients who are prone to hypersensitivity reactions, dexamethasone (20 mg) is administered as 
premedication to PTX (Quock et al., 2002). To our knowledge, mertansine. MMAE, and 
ansamitocin P-3 have not been tested in zebrafish previously for toxicity.  
Zebrafish has been extensively used as a xenograft model for different hematologic and 
solid human tumors as summarized by Drabsch (Drabsch et al. 2017). The zebrafish xenograft 
model presents numerous advantages such as requirement of small spaces for housing, inexpensive 
cost of breeding, EGFP labeled vasculature that makes visualizing angiogenesis feasible, ease of 
xenografting hundreds of animals per experiment, and live microscopy of the entire organism. Few 
limitations are still to be considered when using this model system. One of the limitations include 
incubation temperature, which is different for human cells (37°C) and zebrafish larvae (28°C). To 
overcome the difference in temperature, an optimal temperature was determined (34°C) which 
does not affect the growth of cancer cells or of the zebrafish larvae but is lower than normal human 
body temperature. The lack of an immune system should be considered when performing the 
xenograft assays as in a clinical setting immune cells have a key role in both facilitating as well as 
in eliminating tumor cells. 
The xenograft experiments were performed in three different settings to compare the effect 
of PTX and low and high concentrations of mertansine. The zebrafish were injected with MCF-7, 
BT-474, and MDA-MB-231 cells (n = 12) and treated with 10 nM mertansine (as determined from 
the IC50 from the initial MTS assay) in Trial 1. The rationale behind Trial 1 was to determine if 
the metastatic potential of the three BC cell lines was also represented in vivo. No significant 
differences in the migration pattern of the three cell lines were found to suggest a difference in the 
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migration pattern between these cell lines. Similar results for MCF-7 and BT-474 cells xenografts 
were observed by Eguiara et al., where xenografted single cells derived from BT-474 
mammoshperes, and parental cells from monolayer cultures to observe the migration pattern 
between the two types. They observed higher migration potential in xenografts with 
mammospheres and a weak metastatic potential of the monolayer culture cells, which is consistent 
with what we observed (Eguiara et al., 2011). However, another group found the BT-474 to be 
more metastatic as compared to MCF-7 cells in xenografts (Ghotra et al., 2012). This points to a 
need for understanding the factors that may be involved in the migration of cells in the xenografts. 
Firstly, the experimental factors such as site of injection, number of cells injected, incubation 
temperature, are all to be considered for the migration of cells in the xenografts. Eguiara et al, 
similar to us, injected the BT-474 in the yolk sac of the zebrafish at 2 dpf and the xenografts were 
incubated at 28 as well as 34°C. The only difference was that they injected approximately 500 
cells in each larva. Ghotra et al., on the other hand used the same incubation temperature of 34°C, 
injection site yolk sac, and ~100 cells/larva. It is worthy to note that even with 500 cells, the 
monolayer BT-474 did not show high metastatic potential ((Eguiara et al., 2011), whereas ~100 
cells showed high metastatic potential under the same setting for Ghotra et al. Therefore, the 
number of cells injected can be ruled out to be a factor involved in the aggressiveness of the tumor. 
Other factors such as tumor microenvironment, may also be involved in the metastasis of the cells 
in vivo. Even with an investigation of the various molecular factors that may be involved in tumor 
cells migration in the xenografts, such as VEGF and neutrophils ((He et al., 2012), in metastasis 
of tumor cells to hematopoietic tissues in melnoma xenografts as early as 30 minutes post injection, 
the role of zebrafish tumor microenvironment is not well described in the literature and needs 
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further investigation. 
In these experiments, two different methods of analyzing the data were used to determine 
reduction in tumor burden in treatment groups versus controls. In one method, data was normalized 
to controls to determine the fold change in tumor cells, and in the second method, the percentage 
of cells beyond 500 and 1000 µm were normalized with the total number of cells within that one 
larva. The 10 and 200 nM mertansine were found to be effective in significantly reducing the tumor 
burden in MCF-7 xenografts whereas the same results were not observed for MDA-MB-231 
xenografts. This may be due to less sensitivity of MDA-MB-231 cells to mertansine, although a 
10% reduction in tumor burden was observed in both treatment groups beyond 500 and 1000 µm 
for 10 and 200 nM mertansine, respectively, this change was not significant. Moreover, an increase 
in total number of cells was observed in the MDA-MB-231 xenografts treated with 200 nM 
mertansine as compared to controls. Higher concentrations of mertansine need to be tested to 
determine efficacy in MDA-MB-231 xenografts. 
For MCF-7 xenografts treated with 25 nM PTX, a significant reduction in tumor burden 
was observed in MCF-7 xenografts, when tested using different methods for analysis. This 
indicates an effective positive control for MCF-7 xenografts. In MDA-MB-231 xenografts, a 
reduction in tumor burden was observed in the two experiments with PTX treatment, however, 
this reduction was not statistically significant as compared to controls. This may also point to less 
sensitivity of MDA-MB-231 cells to PTX as observed with mertansine treatment. Treatment with 
higher concentration of PTX is required to further confirm efficacy in the MDA-MB-231 
xenografts. 
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To the best of our knowledge, PTX has not been tested in zebrafish xenografted with breast 
cancer cell lines even though it is one of the most commonly used chemotherapeutics for the 
treatment of breast cancer in humans. Jung et al (2012) tested different concentrations of PTX in 
zebrafish xenografted with oral carcinoma cells (YD10B and HSC-2) and two colon cancer cell 
lines (HCT116 and DLD-1) to observe the effects of PTX on cancer cell dissemination and found 
effectiveness at 100 nM PTX (Jung et al., 2012). In addition to PTX, other standard 
chemotherapeutic drugs that have been tested for validation of the zebrafish xenograft model using 
other human tumor cells include use of rapamycin, (mTOR inhibitor- inhibits lymphangiogenesis 
in zebrafish and mammals) to determine inhibition of  lymphangiogenesis, an important step in 
tumor metastasis; as a positive control to screen compounds with potential inhibition of 
lymhangiogenesis (Astin et al., 2014). 
A significant decrease in both the overall number of cells as well as the distance traveled 
by the MCF-7 cancer cells from the site of injection in the zebrafish xenografts treated with PTX 
was observed. The treatment of the xenografts with mertansine (10 and 200 nM) demonstrated a 
higher survival in the xenografts and a reduction in the total number of cells as well as a decline 
in the number of cells that proliferated and traveled larger distances in the zebrafish from the site 
of injection in the yolk sac to the trunk and tail regions. These results aid us in the validation of 
the zebrafish xenograft model for the screening of anti-cancer compounds for human breast cancer. 
The determination of concentration of the compounds for exposure in xenografts was 
dependent on many factors. The original hypothesis was to use a concentration that was higher 
than the IC50 values, and between the range determined from the MTC and NOAEL observations. 
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However, for PTX, 25 nM (NOAEL) was used, which is lower than the IC50 for PTX. Poor 
solubility of PTX in water was a major drawback for the zebrafish exposures, resulting in use of a 
low concentration stock solution (4 mM) from which smaller dilutions were made and aliquots 
were used to make fresh doses every day for the exposures. However, at 50 and 100 nM 
concentrations, higher incidences of deformities were observed in the larvae, and NOAEL was 
observed at 25 nM which is indicative of interference of PTX at concentrations higher than 50 nM 
to interfere with the molecular mechanisms in zebrafish. A reduction in tumor burden in both 
MCF-7 and MDA-MB-231 xenografts at 25 nM further suggests that the effect of PTX that may 
be due to the effective uptake of the compound from water by the larva. PTX, due to its poor water 
solubility, is administered in mice and humans in a Cremophor solution (polyethyleneglycerol 
tricinoleate) and dehydrated ethanol, and is diluted in 0.9% (w/v) sodium chloride to make a final 
concentration of PTX of 0.3 and 1.2 mg/ml. The pharmacokinetics of PTX are known to be non-
linear and the it is likely that Cremophor contributes to the nonlinearity. A typical injection of 2, 
10, and 20 mg/kg in mice and 2 and 10 mg/kg in humans in Cremphor showed similar levels of 
Cremophor in patients as compared to mice indicating the role of Cremophor in non-linear 
pharmacokinetics of PTX (Willyard, 2018). It is important to note the involvement of vehicles 
such as Cremophor in the pharmacokinetics of drugs while extrapolating the effective 
concentrations of potent chemotherapeutic compounds administered as pharmaceutical 
formulations.  
Mertansine is more potent than PTX, and because of this reason it is being extensively 
investigated in the development of antibody drug conjugates. The high potency of mertansine 
makes it toxic and it has an insufficient therapeutic window (Helft et al., 2004). The solution is the 
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development of ADC’s with the goal to achieve effective and targeted cancer cell cytotoxicity 
without the substantial toxicity mertansine would upon administration as a single agent. The 
monoclonal antibodies bind to the target tissue in a selective manner to reduce the intrinsic toxicity 
to the host tissues and results in an accumulation of the payload in the target tumor tissue (Xie et 
al., 2004). Cantuzumab mertansine (huC242-DM1) is an approved ADC with four molecules of 
mertansine as the payload, humanized monoclonal antibody huC242 (specifically binds to the 
extracellular domain of tumor- associated carbohydrate antigen CanAg (for cancer antigen), a 
glycoform of MUC1, which is strongly expressed in many different solid tumors such as 
pancreatic, colorectal, biliary, gastric, uterine, bladder, and non-small cell lung cancers 
(Baeckström et al., 1991; Xie et al., 2004), and linked by disulfide bonds (Xie et al., 2004). The 
zebrafish xenograft model can be utilized to study the efficacy of ADC’s with different 
combinations of antibodies and linkers with potent payloads in a short-term assay, aiding in rapid 
screening of ADC combinations. This represents a rapidly growing area of drug development and 
approximately 12 ADC’s have been approved by FDA in the past decade alone and different ADC 
combinations are currently being investigated in clinical trials for various cancers. Using a 
zebrafish xenograft to screen the different components for targeted delivery in breast cancer could 
provide important insights to molecular interactions and efficacy for drug development.  
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CHAPTER IV 
FUTURE DIRECTIONS 
Our study successfully developed a xenotransplantation model for the screening of anti-
cancer compounds. Potent microtubule inhibitors that have been studied for decades, were tested 
in zebrafish larvae xenografted with human breast cancer cell lines. Mertansine, ansamitocin P-3, 
and MMAE have not been tested in zebrafish for developmental toxicity or in vivo anti-cancer 
treatment. With the establishment of the xenograft model, we can now study the effects of 
ansamitocin P-3 and MMAE and other components of ADCs in zebrafish xenografted with MCF-
7, BT-474, and MDA-MB-231 cell lines to determine the response of these cell lines to these 
compounds.  
The other two components of the ADC- the linkers and the antibodies will be tested, first 
in zebrafish larvae, and subsequently in xenografts. These studies present their own set of 
challenges owing to larger molecular weight of antibodies and the compatibility of humanized and 
mouse antibodies with zebrafish. This would be a unique opportunity to observe the efficacy of 
various combinations of antibodies and linkers. In several cancer patients, the cancer cells develop 
resistance to conventional therapies and the patient stops responding to treatment. Zebrafish 
xenografts of tumors derived from patients, PDX, are excellent models in the drug discovery field 
and for development of precision medicine as these assays are quick, short, and are useful in 
predicting the anti-cancer efficacy of novel test compounds, and the responses to conventionally 
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used chemotherapeutic drugs in case the tumors develop resistance. In clinical settings, zebrafish 
PDX model offers the advantage of using a large number of larvae which helps in ruling out 
variance in animals, the number of cells required are also less (~200/larva), and the amount of 
compound required for the treatment is also low aiding in efficient medium throughput assays. 
Zebrafish as a PDX model for multiple myeloma (Lin et al., 2016) was shown to exhibit similar 
responses to standard chemotherapeutic drugs used for multiple myeloma (MM) bortezomib and 
lenalidomide, and four novel compounds in dexamethasone resistant and dexamethasone sensitive 
cell lines (MMIR and MMIS, respectively) and subsequently tested the response in patient derived 
xenografts from two newly diagnosed and four relapse MM patients. This study validated the use 
of zebrafish for PDX using primary MM cells. Zebrafish PDX for different solid and hematologic 
tumors presents a research field with enormous potential for exploration and development of novel 
anti-cancer compounds for fast detection of effective therapies tailored for individual patients.  
In this study we were able to develop a human breast cancer zebrafish model based on the 
skeleton established by the work of one of the previous graduate students, Dr. Faisal Albaqami, 
and for the first time in our lab, we were able to quantify, by counting, the proliferation of breast 
cancer cells in vivo. 
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OPTIMIZATION 
 In vitro optimization 
 Transfection vs. Lypophilic dye 
For visualization of BC cells in the xenografts, the cancer cells were fluorescently tagged. 
Initially, the cells were transfected with a red fluorescent protein plasmid pCMV DsRed Express 
2. Upon visualization under a fluorescence microscope, we observed that a small percentage of the 
transfected cells did not exhibit fluorescence. Moreover, the MTS assays performed in transfected 
cells vs parental control cells showed significant sensitivity among the two sets of cells. Therefore, 
we decided to use CM-DiI to label the cells and cells showed fluorescence up to nine days after 
they were labeled (Figure 1). 
 
Figure 21: MDA-MB-231 cells labeled with CM-DiI visualized under TRITC filter. 
 Effect of media on growth of different cancer cells:  
To determine the effect of media on the three different cell lines, BT-474 and MDA-MB-
231 were grown in DMEM supplemented with 10% FBS and 1% P/S 37º C for a period of one 
88 
week and compared the growth (number of cells) with the BT-474 growing in Hybri-Care Medium 
(ATCC® 46-X™) media supplemented with 10% FBS and 1% P/S and MDA-MB-231 cells 
growing in DMEM F12 supplemented with 10% FBS and 1% P/S. We did not observe any 
significant changes in the number of cells growing in the two flasks. Therefore, to eliminate the 
variables, we maintained MCF-7, BT-474, and MDA-MB-231 cell cultures in DMEM 
supplemented with 10% FBS and 1% P/S. 
 Effect of Doxorubicin in zebrafish larvae 
Zebrafish larvae were exposed to different concentrations of DOX (0.5-25µM) over a 
period of 96 hours with replacement of doses every 24 hour and observation for deformities (Figure 
12). At 6.5 µM or higher concentrations, there was an accumulation of DOX in the intestinal cavity 
of the larvae starting as soon as 24 hours post treatment. The accumulation was observed to be 
more in larvae exposed to higher concentrations. The larvae exposed to a concentration of 25µM 
were deformed and did not survive. Moreover, we observed that larvae exposed to DOX, when 
observed under a fluorescence filter (TRITC) exhibited red fluorescence as shown in Figure. This 
was an indication of uptake of DOX by the larvae and provides support to our waterborne 
exposures in the larvae. However, this contradicted with the fluorescence of the CM-DiI labeled 
BC cells and we decided not to use DOX as our positive control. 
89 
 
Figure 20 Pictomicrographs of 4-day old zebrafish larvae after exposure to 12.5 µM DOX for 24 
hours. Image acquired at 10x magnification using brightfield, FITC, and TRITC filters 
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 In vivo optimization 
 Preparation of agar coated petridish for microinjection:  
For injecting zebrafish larvae at 2 and 3 dpf the larvae were placed in a plastic petridish 
positioned dorsally against a glass slide. The larvae were unstable and low survival rate after 
injection was observed. The larvae require an appropriate setup to survive the microinjection and 
at the same time, be stably positioned so the microinjection procedure can be efficiently carried 
out. Therefore, we used low-melting agarose gel (0.1%) to coat the petridish and before the gel 
solidified completely, we used capillaries to make indentations in the gel for positioning the 
embryos for microinjection. This method ensured successful orientation of larvae and 
microinjection in the yolk sac. The larvae were easily transferred to a petridish containing embryo 
water for revival. 
 Determination of optimum temperature for zebrafish and human BC cells: 
Human cell lines are incubated at a temperature of 37°C, at which they grow and proliferate 
normally. Zebrafish embryos, on the other hand, are incubated at a temperature of 28°C for the 
initial five days of their life until they reach the stage where they require an external food source. 
Zebrafish larvae xenografted with human cells cannot survive because of the increase in 
temperature by 9°C and the cells also cannot survive a temperature which is approximately 9°C 
lower than the human body temperature. So, for normal proliferation of BC cells in the fish, and 
normal growth of the larvae, we incubated the larvae and the cells separately at different 
temperatures. We observed that at 34°C, both the fish and the cells grew normally, without any 
deformities in the fish, and normal proliferation of the BC cells. The BC cells, MCF-7, BT-474, 
and MDA-MB-231, were plated in T25 flasks and the cell counts were measured after incubating 
the cells at 37°C and 34°C for 72 hours. No significant differences were observed in the cell 
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numbers. For zebrafish, we incubated zebrafish eggs at 28°C and 34°C and observed the embryos 
after every 24 hours to determine if there were any deformities associated with the increased 
temperature. We observed no deformities at 34°C but the embryos hatched at 2dpf as opposed to 
3 dpf at 28°C.  
 
Figure 21: Percent incidence of larvae incubated at 34 for a period of 4 days for different 
parameters was evaluated. The larvae (n = 48) were placed in a 48 well plate and evaluated for 
survival and deformities such as irregular swimming, curved body axis (bent spine), and 
pericardial and yolk sac edemas. 
 Xenotransplant optimization 
 Injection cell volume: 
The number of cells required per mL to get 100-150 cell in 5 nl cell suspension were 
calculated to be 1x106/ml. The cell suspension was injected from the microneedle on a droplet of 
oil placed on a glass slide and averaged the number of cells in 3 injections from each microneedle. 
The diameter of the injection droplets was measured using a stage micrometer. The image of the 
stage micrometer was captured at the same focus and magnification as the injection droplet. The 
required diameter of the injection diameter to make the injection volume to be approximately 5 nL 
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was 106 mm. The volume was calculated using the formula 4/3 πr3. Additionally, the number of 
cells in each droplet were also manually counted from images of the injection droplet under higher 
magnification (20x) using Nikon Eclipse Ti2 (Figure 22). The number of cells observed from both 
methods were compared to confirm the number of cells/injection. 
Figure 22: Pictomicrographs of injection droplets in oil. A) Image of four consecutive 
injections acquired at 4x magnification. B) Image of injection acquired at 10 x 
magnification. C) Image of two injections acquired at 20x magnification using bright field 
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 Injection time determination: 
To determine the optimum survival of the fish and its ability to sustain the microinjection, 
microinjections in the zebrafish were performed at 0, 1, and 2 dpf. At 0 dpf, the dechorionated 
embryos immediately died from the injections. The larvae were injected at 2 and 3 dpf, and 
observed the xenografted larvae for 6 days post injection. At 3 dpf the larvae were challenging to 
inject as yolk sac was harder to penetrate with the microneedle and most of the injected larvae did 
not retain the cancer cells (upon observation under the fluorescence filter). Whereas the larvae 
injected at 2 dpf exhibited the ability to retain the BC cells and exhibited higher survival rate post 
injection. Therefore, all subsequent microinjections were carried out at 2 dpf. 
 Xenotransplant assay timeline: 
To study the proliferation of BC cells and to determine the effects of treatment on the larvae 
post injection, the survival of the larvae post injection was observed up to 9 dpf. It was observed 
that after 7 dpf, the larvae had a higher mortality rate. And as described in the previous section, 2 
dpf was determined as the optimum time to inject the larvae. Hence, we decided to inject the fish 
at 2 dpf and conduct our evaluation studies until 5 dpi or 7 dpf. The xenotransplantation assay 
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timeline is illustrated in Figure 23. 
 
 Microscopy optimization 
 Mounting medium: 
Imaging individual larvae requires proper mounting material in order to keep the 
anaesthetized larvae in place. Initially, anaesthetized larvae were inserted in warm 1% agarose gel 
(not solidified) and then a drop of the agarose gel along with the larvae was sucked up and placed 
on the glass slide. After imaging several larvae, autofluorescence of agarose gel was observed and 
added a lot of background to the fluorescent images. Thereafter, alternate materials such as gelatin 
and 2% noble agar gel were tested as the mounting gel and observed for autofluorescence. Gelatin 
exhibited autofluorescence. For noble agar, a 2% noble agar gel solidified within an 
immunohistology chamber was used and a groove was carved in the gel to house the anaesthetized 
larvae for imaging. However, the volume of tricaine around the fish had to be optimized to ensure 
Figure 23: Timeline of the Xenotransplant Assay 
95 
that the tricaine did not dry up from the heat emanating from the laser of the microscope lens. We 
observed that noble agarose did not autofluoresce and did not interfere with the fluorescence signal 
of the fish. Additionally, as suggested by Dr. Joshua Bloomekatz, we utilized electric tape to 
construct an elevation on a coverslip and cut out the tape forming a rectangular space (Figure 5) 
and anaesthetized larvae was placed onto the space in tricaine and covered using another coverslip. 
This provided an enclosure for the larvae and provided the opportunity to enhance our field of 
view of the larvae. We obtained much clearer images using this technique. 
  With the arrival of Nikon Eclipse Ti2, we were able to image fish in a 48 well plate using 
(0.08%) low melt agarose. This was much faster, had better image quality, and we were able to 
image more fish in the same period of time. 
 
Figure 24: Elevation created using electrical tape on a coverslip for mounting anaesthetized 
zebrafish larvae for imaging under fluorescence microscope. The anaesthetized larvae were stable 
in this setting for 4-5 hours 
 Quantification of breast cancer cell proliferation via PCR  
 Real Time PCR in cells 
For our studies, it was important to identify a gene that is expressed by BC cells but not 
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constitutively expressed by normal zebrafish cells to compare the effect of treatment with 
candidate compounds versus controls. As CYP1B1 is frequently expressed in human BC, we chose 
this as our gene of interest. The CYP1B1 primers used were previously published (Lin et al. 2003). 
In zebrafish, two types of CYP1 family genes have been characterized. cyp1a is expressed in liver 
and cyp1b1, cyp1c1 and cyp1c2 are transcribed in the heart and eye in adult zebrafish. During 
development, cyp1b1 is expressed maximally within 2-3 dpf, with specific expression in ocular 
cells, diencephalon, and the midbrain-hindbrain boundary determined by whole-mount RNA in 
situ hybridization analysis (Yin et al. 2008). So, we selected human CYP1B, specifically expressed 
in the three cancer cell lines, as a marker of tumor cell expression and proliferation in zebrafish 
larvae xenotransplanted with human breast cancer cells.  
To detect the expression of CYP1B1 in MCF-7, BT-474, and MDA-MB-231 cells, the cells 
were plated in 12 well plates at the density of 2.5x105 cells/well in 1 mL of DMEM and incubated 
at 37ºC supplemented with 5% CO2. At 90% confluence, cells were detached using trypLE 
EXPRESS (ThermoFisher Scientific, CA)). TrypLE was neutralized using equal volume of 
DMEM and cells were centrifuged at 4000 rpm (2670 x g) for 5 minutes. Cells were counted, and 
1 x106 cells were used for mRNA extraction. Cell pellet was lysed with lysis buffer (Thermo 
Scientific, CA) supplemented with 2% β-mercaptoethanol. Further extraction of mRNA was 
conducted using GeneJET RNA purification kit and as instructed by manufacturer (Thermo 
Scientific, CA). The concentration of mRNA quantified using Nanodrop 2000, and the purity of 
mRNA was determined by assessing the A260/A280 ratio and samples with values >2 were used for 
further experimentation. The RNA samples were reverse-transcribed to cDNA using Taqman® 
Reverse Transcription reagents (Applied Biosystems, CA): random hexamers, Multiscribe 
Reverse Transcriptase, RNase inhibitor, deoxyNTP mix, 25 mM MgCl2, 10xRT buffer in 25 µL 
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reaction. The temperature program used was 25 °C for 10 min, 37 °C for 60 min and 95 °C for 5 
min. RT-qPCR was performed in Applied Biosystems 7200 using SYBR Green (Applied 
Biosystems, Massachusetts) and the parameters used were: 95 °C for 10 min, then 40 cycles of 95 
°C for 15 sec and 60 °C for 1 min, followed by 95 °C for 15 sec, 60 °C for 1 min, 95 °C for 15 sec 
dissociation curve. CYP1B1 and 18S were amplified in duplicate in separate reactions on the same 
plate. The fold induction of CYP1B1 mRNA in xenotransplanted zebrafish relative to non-injected 
larvae were normalized to 18S given by formula =2-ΔΔCT as described by (Livak and Schmittgen, 
2001), where CT was the threshold cycle indicating the fractional cycle number corresponding to 
the threshold attained by the amplified CYP1B1. 
Table 7: RT-qPCR primers 
 RT-qPCR in zebrafish 
 To detect CYP1B1 in xenografted larvae and to confirm that human CYP1B1 was not 
expressed in un-injected larvae, zebrafish larvae xenotransplanted with the breast cancer cells were 
pooled (20 fish per vial repeated twice) at 1 dpi and 5 dpi in RNA later and stored at -80 ºC until 
we performed RNA isolation on them. RNA was isolated from the larvae using TRIzol (Invitrogen, 
Massachusetts), RNase-Free DNase set (Qiagen, California), and RNeasy mini kit (Qiagen, 
California) using manufacturer’s protocol. The extracted RNA was then quantified on a NanoDrop 
CYP1B1 
F: 5'-GCTGCAGTGGCTGCTCCT-3' 
R: 5'-CCCACGACCTGATCCAATTCT-3' 
18S 
F: 5'-TGG TTA ATT CCG ATA ACG AAC GA-3' 
R: 5'-CGC CAC TTG TCC CTC TAA GAA-3' 
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2000 (ThermoFisher Scientific, Massachusetts) and samples were evaluated for acceptable 
A260/A280 ratio. Further reverse-transcription and RT-qPCR were performed as described above. 
The statistical significance from RT-qPCR results was analyzed using one-way ANOVA and 
Tukey’s post hoc test where statistical significance was found to be at p ≤ 0.05. RT-qPCR results.  
Human CYP1B1 was measured using RT-qPCR in the three cancer cell lines MCF-7, BT-
474, and MDA-MB-231, and in zebrafish xenografted with MCF-7 and MDA-MB-231 cells. Un-
injected zebrafish larvae were also quantified to detect any expression. Expression of CYP1B1 
was detected in all three cell lines and the xenograft larvae, but not detected in un-injected larvae. 
To our knowledge, the expression of a gene as a quantitative method to determine the effect 
of anti-cancer compounds has not been done before and represents an additional method that can 
be used to validate the effect of treatment. Although, high concentration of mRNA from zebrafish 
xenografts could not be extracted, the expression of CYP1B1 in the breast cancer cell lines and 
the xenografted fish was detected. 
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